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INTRODUCTION 
       Sir William Osler in year 1898 had described pneumonia in the elderly as “The 
friend of the aged, allowing them a merciful relief from those cold gradations of 
decay, that make the last state of all so distressing”. Pneumonia is one of the most 
common infectious illness encountered in the clinical practice1.   
         Pneumonia is an infection in lung parenchyma due to proliferation of 
pathogenic microorganisms at alveolar level and due to varied response of host 
towards these pathogens results in varied clinical symptoms 2. 
      In general population, infection that is frequent and accounting for larger 
number of working days lost is the respiratory tract infection3. Pneumonia being the 
major cause of morbidity worldwide mainly in developing countries with varied 
etiology pathogenesis, clinical presentation and epidemiology, early diagnosis of 
etiological agents and administration of specific antimicrobial treatment reduces 
complication and improves the prognosis. As per WHO estimation of adult 
pneumonia prevalence in South East Asia region, India accounts for about 4% 4.  
Even though pneumonia accounts for more numbers of morbidity and mortality, it 
still has been underestimated, not properly diagnosed and treated2. 
        Clinically pneumonia can be classified as Community acquired pneumonia 
(CAP) and Nosocomial pneumonia. Nosocomial pneumonia is further classified in 
to Hospital acquired pneumonia (HAP), Ventilator associated pneumonia(VAP)  
and Health care associated pneumonia (HCAP). 
 
 
 According to Infectious disease society of America (IDSA), Community 
acquired pneumonia (CAP) is defined as an acute onset of infection in the lung 
parenchyma associated with few symptoms, radiological evidence, auscultatory 
signs pertaining to pneumonia in patients who is not admitted in hospital or in any 
health care facility for greater than 14 days prior to the symptom onset3. 
Microorganisms causing Community acquired pneumonia includes Streptococcus 
pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Gram negative 
bacilli such as Klebsiella pneumoniae, Pseudomonas aeruginosa2. Delay in 
diagnosis and associated risk factor of community acquired pneumonia may lead to 
complications like pleural effusion, lung abscess, bacteremia and empyema 4. 
  Hospital acquired pneumonia (HAP)- As per IDSA, pneumonia occurring 
after more than fourty eight hours of duration of stay in hospital without any 
previous symptoms of pneumonia 5. Multidrug resistant pathogen (MDR) and 
polymicrobial infections associated with anaerobes is a complicating microbial 
etiology  in HAP2  .It increases the duration of stay in hospital of about seven to nine 
days per patient with also a economical burden to hospital7. 
  Ventilator associated pneumonia (VAP) - Infection occurring in patients 
admitted in Intensive Care Unit (ICU) who is on mechanical ventilation for more 
than 48 hours of intubation 5,6,8,9. Due to occurance of Multidrug resistant pathogen 
(MDR) such as MRSA, Pseudomonas aeruginosa, Acinetobacter spp and with 
inadequate antibiotic therapy results in poor patient prognosis which can be 
corrected by early diagnosis and administration of specific antibiotics at the earliest, 
so that morbidity and mortality rates can be lowered9.  
 
 
          Health care associated pneumonia (HCAP)- Due to multiple risk factor in 
patients , they should be considered individually because of the emergence of 
multidrug resistant pathogen commonly MRSA.  Recurrent pneumonia is a 
complication due to necrotizing infection of lungs2. 
 In all categories of pneumonia, multidrug resistant pathogen includes 
Methicillin  resistant Staphylococcus aureus (MRSA) in Gram positive isolates and 
Extended spectrum betalactamases (ESBL) producers in Gram negative bacilli has a 
major role in morbidity and mortality. Gram negative bacteria is the leading cause 
of pneumonia in the hospitalized patients due to longterm intake of antibiotics, 
surgery, trauma, malnourishment, tumor 10. Ineffectiveness of antibiotics and 
increase in the severity of illness is due to quick spread of Extended spectrum 
betalactamases resistant pattern in to various pathogenic strain causing 
pneumonia11.  
 Methicillin  resistant Staphylococcus aureus (MRSA) expresses modification 
in pencillin binding protein (PBP2a) which leads to resistance of betalactam 
antibiotics. Change in resistance pattern of MRSA has lead  to changes in antibiotic 
policy, health awareness with education and infection control measures which will 
reduce the disease burden of MRSA 12 . 
 Pneumonia remains a significant medical problem despite the advent of 
antibiotics, improved diagnostic and microbial techniques and sophisticated 
respiratory support system. Inorder to circumvent this problem due to resistance 
pattern of MDR isolates, gaining of knowledge about the local resistance  pattern is 
 
 
important to treat the infection with appropriate antibiotics and this can be achieved 
by conducting a local surveillance program13. 
 This study aimed at studying the organisms distribution pattern  in each 
categories of pneumonia by isolation, identification and characterization by 
standard microbiological technique with their antibiotic sensitivity pattern . The 
resistant organisms was screened for MRSA and ESBL followed by confirmation as 
per CLSI guidelines. Thus early diagnosis and effective treatment will reduce the 
local burden of the disease pattern, complications of pneumonia and knowing the 
antibiotic sensitivity pattern will  help to formulate an antibiotic policy  institutional 
patient care. 
    
                                            
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVE 
1. To isolate, identify and characterize bacteria from adult patients with 
pneumonia. 
 
2. To find out the antibiotic susceptibility pattern of the bacterial isolates. 
 
3. To detect the Extended Spectrum Beta Lactamases (ESBLs), 
Metallobetalactamases, AmpC Beta Lactamases producers from Gram 
negative bacterial isolates. 
 
4. To find the prevalence of Methicillin Resistant Staphylococcus aureus 
(MRSA) among Staphylococcus aureus isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
         About 2500 years ago Hippocrates described pneumonia and Sir William 
Osler said that pneumonia as “Captain of the men of death”. Pneumonia is an 
infection in lung parenchyma due to proliferation of pathogenic microorganism at 
alveolar level and due to varied immune response of  host towards these pathogens, 
it presents as clinical symptoms 2 . 
 
EPIDEMIOLOGY: 
          Approximately more than six lakh individual admitted in hospital and 45 
thousand death due to Pneumonia observed worldwide annually. Pneumonia is the 
5th leading cause of death in the world14. Estimated prevalence of Pneumonia 
affecting adults in India is about 4%4. Due to the association with risk factor such as 
COPD, smoking, males are commonly affected and people between age group of 
51-60 yrs are also affected due to chronic ailments. 
           In India, mortality rate of Community acquired pneumonia CAP lies between 
3.3-11%4. Hospital acquired pneumonia (HAP) accounts for about 13-18% of all 
nosocomial infection and affects only 0.5- 2%15 of hospitalized patients with 
mortality rate from 20-50%. (Hoffkenet al)16,17. In the study done by Vasuki et al18 
in Tamilnadu, the incidence of HAP is 10.3%. Patient on mechanical ventilation 
have rates of pneumonia 7 to 21 folds higher than patient not on ventilator support. 
Rate of infection is twice high in teaching institution when compared to small 
institution. Ventilator associated pneumonia (VAP), overall incidence in ICU ranges 
about 15-40%19 and mortality rate is about 40-50% 20, 21, 22. 
 
 
CAUSATIVE ORGANISMS  OF PNEUMONIA23: 
Bacteria - Streptococcus pneumoniae, Haemophilus influenzae,  
Mycoplasma pneumoniae, Chlamydophila pneumoniae, pseudomonas aeruginosa, 
Enterobacteriaceae, Peptococcus, Prevotella, Actinomyces, Nocardia spp, 
 Coxiella burnetii, Mycobacteria spp.  
Virus - Respiratory syncytial virus, Influenza, Parainfluenza virus type1,2,3. 
Rhinovirus, Human Metapneumovirus, Adenovirus (type 4and7). 
Parasites – Paragonimus westermani, Ascaris lumbricoides,  
Strongyloides stercoralis, Toxoplasma gondii. 
Fungi – Histoplasma capsulatum, Coccidioides immitis, Mucor spp,  
Pneumocystis jirovecii, Rhizopus spp, Absidia spp. 
 
PATHOPHYSIOLOGY 2: 
 The lung has been frequently exposed to the particulate things, gaseous 
mixture and numerous microorganism present in inspired air. In addition, seeping 
down of oral secretions from the upper respiratory tract occurs which leads to 
microaspiration. The lower respiratory tract are maintained sterile due to defense 
mechanisms of the respiratory tract (nasal hair, mucociliary clearance, gag reflex, 
cough mechanism).  
 The acute pulmonary infection is developed due to either a defect in host 
defenses, exposure to a particularly virulent microorganism .Infectious agents gain 
entry to the lower respiratory tract through aspiration of upper airway resident flora, 
inhalation of aerosolized material and less frequently, metastatic seeding of the lung 
 
 
from blood. Alveolar macrophages ingest the pathogens and initiate an 
inflammatory response which triggers the clinical symptoms of pneumonia.  
 
PATHOLOGY2,24 : 
Classic pneumonia evolves through a series of pathologic changes. 
 Congestion /Edema- with the presence of a proteinaceous exudates, and 
bacteria in the alveoli.  
 Red hepatization - presence of erythrocytes, neutrophils in the cellular 
intraalveolar exudate . During this phase, occasionally bacteria may be seen 
in the culture. 
 Gray hepatization- no new extravastion of   erythrocyte and those already 
existing are lysed and degraded. Neutrophil is the predominant cell, 
abundant fibrin deposition, and absence of bacteria which is sign of 
improving from infection. 
 Resolution -The dominant cell type in the alveolar space is the macrophage, 
and bacteria, fibrin, debris of neutrophils has been cleared. 
  
Because of the microaspiration mechanism, bronchopneumonia pattern is 
mostly seen in nosocomial pneumonias, whereas a lobar pattern in bacterial 
CAP. 
RISK FACTORS  2, 25,  26: 
 With advanced age group, smoking, alcohol consumption and the presence 
of coexisting illness like COPD, diabetes, chronic lung disease, renal failure, 
congestive cardiac disease and neurological illness, influence the outcome of 
 
 
disease in CAP25. Addition to these prolonged intakes of antibiotics and increased 
hospital stay influences the outcome of disease in nosocomial pneumonia. 
CLASSIFICATION OF PNEUMONIA: 
Pneumonia may be classified according to its anatomical location in the lung24: 
 Lobar pneumonia occurs in one part, or lobe, of the lung. 
 Bronchopneumonia tends to be scattered throughout the lung. 
 Clinically pneumonia can be classified as per place of acquisition, 
Community acquired pneumonia (CAP) and Nosocomial pneumonia. Nosocomial 
pneumonia is further classified in to Hospital acquired pneumonia (HAP), 
Ventilator associated pneumonia (VAP)  and Health care associated pneumonia 
(HCAP)2. 
1. COMMUNITY ACQUIRED PNEUMONIA: 
 CAP can be defined both on clinical and radiographic findings27.  According 
to Infectious disease society of America(IDSA), Community acquired 
pneumonia(CAP) is defined as an acute onset of infection in the lung parenchyma 
associated with few symptoms, radiological evidence, auscultatory signs pertaining 
to pneumonia in patients who is not admitted in hospital or in any health care 
facility for greater than 14 days prior to the symptom onset3. 
CASE DEFINITION OF CAP25, 28, 29: 
 New or progressive infiltration in Chest Xray with atleast any two of the 
following symptoms: cough (>4 weeks), purulent sputum production, fever 
(temp.>37.8ºC) or total WBC count >10,000/mm3.  
 
 
ETIOLOGY AGENTS IN CAP2: 
Outpatient setting- Streptococcus pneumoniae, Haemophilus influenzae, 
Mycoplasma pneumoniae, Chlamydophila  pneumoniae and other respiratory 
viruses [Respiratory syncytial virus, Influenza, Parainfluenza virus type1,2,3. 
Rhinovirus, human metapneumovirus,  Adenovirus (type 4and7)]. 
 
Inpatient setting- 
 NON –ICU-- Streptococcus pneumoniae, Haemophilus influenzae, 
Chlamydophila  pneumoniae ,Mycoplasma pneumoniae, Legionella pneumophila. 
 ICU- Streptococcus pneumoniae, Legionella pneumophila, Haemophilus 
influenza, Staphylococcus aureus, Gram negative bacilli. 
 The causative  bacterial  agents  of  CAP in  India varies with geographical 
distribution.for example, the leading causative agent in Shimla and Delhi  is 
Streptococcus pneumoniae  whereas in Ludhiana Pseudomonas aeruginosa  
predominates 25. 
2. HOSPITAL ACQUIRED PNEUMONIA: 
 HAP is an inflammation of lung tissue by a pathogen neither present nor at 
incubation period during the time of hospital admission27.As per IDSA, pneumonia 
occurring after more than fourty eight hours of duration of stay in hospital without 
any previous symptoms of pneumonia6. Due to HAP, duration of hospital stay is 
increased by an average of 7-9 days per patient with increase in financial burden7.  
 
 
 
CASE DEFINITION OF HAP27, 30: 
             New or progressive infiltration in Chest X-ray with atleast any two of the 
following symptoms: cough (>4 weeks), purulent sputum production, fever 
(temp.>37.8ºC) or total WBC count >10,000/mm3 occuring in patients admitted in 
hospital for after more than fourty eight hours without any prior symptoms of 
pneumonia. 
ETIOLOGY AGENTS IN HAP31, 32, 33: 
 Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, 
Klebsiella pneumoniae, Proteus spp, Serratia marcescens, Haemophilus influenza. 
3. VENTILATOR ASSOCIATED PNEUMONIA34: 
 Ventilator associated pneumonia(VAP)-Infection occurring in patients 
admitted in Intensive Care Unit(ICU) who is on mechanical ventilation for more 
than 48 hours of intubation8, 7. VAP can be acquired in many routes including 
aspiration of oropharyngeal organism, hematogenous spread, MRSA and MDR 
pathogens from hands of health care workers, contaminated medical equipment7 . 
Classification of VAP7,8 : 
Based on duration of mechanical ventilation 19,  
A. Early onset VAP- Occurs in first four days on ventilator  with possible 
causative agents being Enterobacteriacea and Staphyococcus aureus ,carries 
better prognosis. 
 
 
B. Late onset VAP- occurs in patient with five days or more on  ventilator 
mainly due to nonfermenting GNB associated with MDR pathogens. 
mortality and morbidity rate is high. 
 Estimated risk of VAP with hospital stay is high in early as 3% /day for first 
five days of ventilation, 2% / day during 5-10 days of ventilation and 1%/day after 
10 days of ventilation7. 
Case definition of VAP 13,35: 
Patient is on mechanical ventilation for more than 48 hours with suspected VAP , 
New and persistant chest infiltrate in chest radiograph with any of these 2 criteria: 
 Fever (temp.>38ºC) or hypothermia (<36 ºC). 
 WBC Count ≥10000 mm3 or ≤ 4000mm3. 
 Purulent tracheal secretion. 
ETIOLOGY AGENTS IN VAP 2: 
 MDR Pathogens- MRSA, Pseudomonas aeruginosa, Acinetobacter 
baumanii, ESBL-positive strains Klebsiella pneumoniae, Antibiotic-resistant 
Enterobacteriaceae, Legionella pneumophila, Enterobacter spp,  Burkholderia 
cepacia. 
 Non-MDR Pathogens - Streptococcus pneumonia, MSSA, Klebsiella spp, 
Haemophilus influenza, Escherichia coli, Proteus spp, Serratia marcescens, 
Aspergillus spp. 
 
 
Clinical criteria of VAP7, 8, 36, 37, 38: 
 The Pugin’s modified Clinical Pulmonary Infection Score (CPIS), which 
combines clinical, radiographic, physiological and microbiological data into a single 
numerical result, is used as a diagnostic tool for VAP. Modified CPIS > 6 is 
considered as diagnosis of pneumonia. 
Microbiological  Criteria of VAP37: 
 >25 PMN cells with few epithelial cells in Gram stained smear of ETA 
sample and Significant quantitative culture (colony count ≥105 cfu/ml). 
4.HEALTH CARE ASSOCIATED PNEUMONIA(HCAP)39: 
 Patient admitted in hospital for ≥2 days within 90 days of diagnosis of 
pneumonia, receiving I.V. antibiotics, residing in health care facility <30 days or 
received hemodialysis. Multidrug resistant pathogens are the major causative 
organism. 
CLINICAL FEATURE OF PNEUMONIA2: 
Symptoms - fever, cough (productive/non productive), shortness of breath, pleuritic 
type of chest pain. 
Signs - tachycardia, tachypnoea, dull note on percussion, rales/ronchi/diminished 
breath sounds on auscultation. 
 
Criteria for hospital admission: 
 To provide an efficient patient care, criteria has been laid down for patient in 
need of hospital care.  
 
 
1.Pneumonia Severity Index (PSI) scoring:  
The pneumonia severity index (PSI) was developed to categorize patients for 
hospital care 39.                       
Patient characteristic                                                     Points 
Demographic   
Age(years):   
Male: age   - 
Female: age - 
Nursing home resident +10 
Co- morbidities 
 Neoplastic disease  +30 
 Liver disease   +20 
Congestive heart failure  +10 
Cerebrovascular disease    +10 
Renal disease   +10 
Examination findings 
 Altered mental status  +20 
Respiratory rate  30/minute +20 
Systolic blood pressure <90 mmHg +20 
Temperature <35ºC or 40ºC    +15 
Pulse rate125/minute  +10 
Laboratory findings 
 pH <7.35 (do ABG only if hypoxic or COPD) +30 
BUN >10.7 mmol/ L      +20 
Sodium <130 mEq/L +20 
Glucose 13.9 mmol/L  +10 
Hematocrit <0.30         +10 
PaO2 <60mmHg or oxygen saturation <90%   +10 
Pleural effusion   +30 
 
 Patients with a higher risk are defined as being in PSI risk class V (PSI-V) 
 PSI score > 130. 
2.CURB 65 Criteria: Confusion, Urea(>7mmol/L), Respiratory rate ≥30/mt,          
Blood pressure systolic  ≤  90mmHg  or   diastolic ≤  60mmHg,  Age( ≥65 years). 
 
 
COMPLICATION OF PNEUMONIA24: 
 Abscess formation particularly seen in type 3 pneumococci, Klebsiella 
pneumoniae , Staphylococcus aureus. 
 Bacterial dissemination to brain, kidney ,spleen and joints. 
 Empyema - infection spreading to pleural cavity and most common 
with infection of  pneumococcus40. 
LABORATORY DIAGNOSIS4: 
  Total Leucocyte Count, Differential Count,  Erythrocyte sedimentation rate , 
Sputum Microscopy for Gram Stain, Acid Fast  Bacilli, Sputum culture and 
sensitivity, Chest X-ray PA view, Computerised Tomography Thorax (if necessary), 
Arterial blood gas analysis(VAP), Biomarkers-C-Reactive protein, Procalcitonin, 
sTREM-1(soluble triggering receptor expressed on myeloid cells)5. 
 
MICROBIOLOGICAL INVESTIGATION 
COLLECTION OF SPECIMEN41 : 
1. SPUTUM42, 43, 44: 
          Sputum is a mixed collection of bronchial secretion and inflammatory 
exudates from affected lobe of lung parenchymal tissue that is coughed up in to the 
mouth and expectorated. Sputum should be differentiated from saliva, as sputum is 
purulent, opaque, viscus and yellow to green coloured whereas saliva is clear and 
watery in nature. 
 
 
 
Instruction for sputum collection 41,45,46: 
1. Sputum is collected prior to the administration of antibiotics. 
2. Sputum is collected in the early morning as soon as the patient awakes and 
asked to brush the teeth and then rinse the mouth with water before 
collection. 
3. Sputum is collected in a disposable, sterile, wide mouthed, screw capped 
plastic container of about 100ml capacity. 
4. Sputum can be collected by asking the patient to deeply cough out the 
sputum spontaneously or   induced by administering saline nebulisation, 
postural drainage or by appropriate physiotherapy. 
5. Sputum sample collected in the container is transported to laboratory for 
processing within 2 hours of collection. 
Processing of sputum: 
Homogenisation: 
 Purulent part of the sputum has the appropriate pathogen that is overlaid by 
clear to mucoid secretion. Homogenisation is done to make uniform mixture of  the 
relavant pathogen to be  present in the sample , so as each drop of the sample will 
contain some amount of pathogen that can be suitable for smear preparation and 
culture. 
a. Equal volume of sputum sample and sodium dithiothreitol is mixed in a 
vortex mixture for about fifteen seconds and allow it to stand for about 
fifteen minutes in room temperature. 
 
 
b.  Equal volume of sputum sample and buffered pancreatin solution is mixed 
continuosly and gently in a machine that tilt to and fro and incubated at 
37ºC for thirty minutes. 
2) ENDOTRACHEAL ASPIRATE (ETA)6,45,47 
 Endo Tracheal aspirate (ETA) was collected from the patient who has been 
in mechanical ventilation for more than fourty eight hours with suspected VAP. One 
milliliter of  ETA  was collected in a sterile screw capped plastic container  by using 
twenty two inch Ramson’s  12 F suction catheter with a mucus extractor  was 
introduced slowly in to the endotracheal tube for about a distance of twenty five to 
twenty six centimeter. 
 
3) BRONCHOALVEOLAR LAVAGE (BAL)48: 
 30-50ml of sterile saline is injected in to the fibreoptic bronchoscope which 
is threaded to peripheral bronchiolar ramification and it is aspirated, collected in a 
sterile container. 
4) BLOOD45,48 : 
 Blood culture was performed in all cases of suspected pneumonia with fever 
(temp.>37.8ºC) prior to starting antibiotics. Sterile gloves were worn prior to the 
procedure and a patch of skin prepared approx. 5-cm in diameter over the proposed 
veni-puncture site. This area was cleansed thoroughly with 70% isopropyl alcohol, 
followed by povidone iodine, and followed again by 70% isopropyl alcohol in a 
concentric circles moving outward from the centre. 
 The skin was allowed to dry for at least 1 minute before the sample is 
collected 5 ml sample of blood was collected by venipuncture using sterile syringe 
 
 
and transferred after removing the needle into the blood culture bottle containing 50 
ml of Brain heart infusion broth, maintaining sterile aseptic precautions.  
Direct Microscopy: 
 Smear is made from the homoginsed or purulent material of the sputum. 
Gram staining was done and examined under oil immersion field for the relative 
number of squamous epithelial cells and neutrophil. 
BARLETT’S GRADING: 
 
 
 
 Average number of neutrophils and epithelial cells for 20-30 LPFs was 
calculated and the total score arrived. A score of 0 or lessthan 1 is indicative of 
contamination and a score of 1 and above was considered an acceptable quality of 
sample. 
MURRAY AND WASHINGTON GRADING48: 
 Epithelial cells/lpf Leukocytes /lpf 
Group 1 25 10 
Group 2 25 10 - 25                 
  Group 3 25 25 
Group 4 10 – 25 25 
Group 5 <10 25 
Only Group 5 specimen is accepted for culture. 
Number of 
epithelial 
cells 
Grade 
10 - 25 -1 
>25 -2 
Number of neutrophil 
(lpf) 
Grade 
 <10 0 
10 – 25 +1 
>25 +2 
 
 
 An acceptable ETA samples in Gram stained smear shows less than ten 
squamous epithelial cells per low power or organisms under oil immersion field. 
Best ETA samples in Gram stained smear showed >25 polymorphonuclear 
leucocytes per low power field with minimal squamous epithelial cells8,45     
3. CULTURE41,45,48:  
 Sputum samples were then plated into the following agar media: Nutrient 
agar, 5% Sheep blood agar, Chocolate agar and Mac Conkey agar. All cultures were 
incubated at 37°C under aerobic condition and addition to this blood agar and 
Chocolate agar also require 5-10% carbon dioxide atmosphere. Plates were 
evaluated for growth at 24 and 48 hours. 
 Endotracheal aspirate, bronchoalveolar lavage specimens were subjected to 
quantitative culture. All material is resuspended in the fluid and three serial 
dilutions are made (1/10, 1/1000, 1/100,000). These dilutions 0.01 ml is plated out 
in 5% Sheep  Blood agar and incubated at 37°C under  5-10% carbon dioxide 
atmosphere for about 18-24 hours6,49 . 
 The number of bacteria in the quantitative culture of ETA samples were 
expressed in colony-forming unit (cfu) per milliliter.(cfu/ml = number of colonies 
×dilution factor ×inoculation factor) Quantitative threshold of organism is colony 
count of ≥105 cfu/ml in ETAand ≥104 cfu/ml BAL is consistent with pathogen and 
not a colonizer8,50. Bacterial isolates grown in culture were identified by means of 
Gram’s staining and biochemical reactions by standard microbiological techniques51 
. 
 
 
 
Blood culture: 
 The inoculated  blood culture bottles were incubated at 37°C and examined 
after 18 to 24 hours for any turbidity, discoloration or clotting. The first subculture 
was done onto Nutrient agar, blood agar and Macconkey agar plates and incubated 
aerobically at 37°C  with 5-10% CO2 for about 18-24 hours. These bottles were 
reincubated and checked for turbidity twice daily. 
 
ANTIBIOTIC SUSCEPTIBILITY TESTING52 
 Antibiotic sensitivity testing was done on Mueller Hinton agar using Kirby 
Bauer disk diffusion method. Interpretation of the results was done by measuring 
the sizes of the zone of inhibition according to CLSI guidelines 2015(M-100-S25). 
SEROLOGY-Antigen Tests2,53,54,55: 
 Legionella antigens in urine detects only serogroup1 (accounts for 
community acquired infection) with 90% sensitivity and 99% specificity. 
 Chlamydial antigen (LPSAg) can be demonstrated by  ELISA or micro 
immunofluorescence method. 
 Pneumococcal urine antigen test is also quite sensitive and specific (80% and 
>90%, respectively).  
MANAGEMENT OF PNEUMONIA2,5: 
1.COMMUNITY ACQUIRED PNEUMONIA56: 
Outpatients- 
 without comorbidities: Azithromycin [500 mgPO once, then 250 mg qd] or 
Clarithromycin [500 mg PO bid] , Doxycycline (100 mg PO bid). 
 
 
 with comorbidities: respiratory   fluoroquinolone (levofloxacin [750 mg PO 
qd] moxifloxacin [400 mg PO qd], gemifloxacin [320 mg PO qd]) or            
β-lactam amoxicillin [1g tid] or amoxicillin/clavulanate [2g bid] or 
ceftriaxone [1–2 g IV qd] , cefuroxime [500 mg PO bid])   cefpodoxime [200 
mg PO bid], with  a macrolide. 
Inpatients: 
 Non-ICU- respiratory   fluoroquinolone  (levofloxacin [750 mg PO qd] 
moxifloxacin [400 mg PO qd] , gemifloxacin [320 mg PO qd]) β-lactam 
antibiotics  (ampicillin [1–2 g IV q4–6h], cefotaxime [1–2 g IV q8h], ., 
ceftriaxone [1–2 g IV qd], ertapenem [1 g IV qd]) with a macrolide (oral 
clarithromycin or azithromycin or IV azithromycin[1 g once, then 500 mg 
qd]) 
 ICU- β-lactam  antibiotics  (ampicillin-sulbactam [2 g IV q8h], ceftriaxone 
[2 g IV qd], or cefotaxime [1–2 g IV q8h]) with either fluoroquinolone or 
azithromycin . 
Special Consideration: 
 CA-MRSA: Add vancomycin (15 mg/kg q12h) or linezolid (600 mg IV 
q12h). Pseudomonas aeruginosa- antipseudomonal β-lactam antibiotics 
(Meropenem [1 g IVq8h]) , Imipenem [500 mg IV q6h], Piperacillin/tazobactam [4. 
5 g IV q6h], Cefepime [1–2 g IV q12h], with either of fluoroquinolone 
{Levofloxacin (750 mg IV qd) or Ciprofloxacin (400 mg IV q12h)}or an 
aminoglycoside (Tobramycin [1. 7 mg/kg qd])  or Amikacin [15 mg/kg qd] . 
 
 
 
2.NOSOCOMIAL PNEUMONIA57: 
a.Patient without  risk of MDR pathogen- 
 Ampicillin /sulbactam I.V. - 3g 6th hourly or Cefotaxime (q 6hr) 
/Ceftriaxone(q 24hr) -2g I.V or Moxifloxacin I.V.-400mg q24 hr or Ertapenem I.V.-
1g  q24 hr. 
b.Patient with risk of MDR pathogen- 
 Linezolid (600 mg IV q12h) or Vancomycin (15 mg/kg q12h) for  Gram 
positive bacteria along with β-lactam Ceftazidime (2 g IV q8h) or cefepime (2 g IV 
q8–12h) or Piperacillin/tazobactam (4. 5 g IV q6h) or Imipenem (500 mg IV q6h or 
1 g IV q8h), or meropenem (1 g IV q8h)  plus Ciprofloxacin (400 mg IV q8h) or 
levofloxacin (750 mg IV q24h), Gentamicin or tobramycin (7 mg/kg IV q24h) or 
amikacin (20 mg/kg IV q24h) for  Gram-negative  bacteria. 
 
BACTERIAL RESISTANCE58: 
 Mechanism by which microrganism showing resistance to antibiotics are due 
to production of certain enzymes (β-lactamases) destroy active form of drug are 
produced by some microorganism, alteration in the drug permeability, alteration in 
the target site or metabolic enzymes responsible for drug action. Drug resistance 
may be non genetic (showing phenotypic resistance)or genetic(mutation in 
chromosome /plasmid mediated resistance) by origin. 
 
 
 
 
 
BETALACTAMASES 
 This is a heterogeneous group of penicillin recognizing proteins. They 
belong to members of super family of active site serine protease. These enzymes 
inactivate β-lactam antibiotics (Penicillin, Cephalosporins). 
CLASSIFICATION OF BETA LACTAMASES 
Schemes of functional classification that were accepted by β-lactamase 
researchers include: 
(i) In 1968, Cephalosporinases and penicillinases were grouped on the basis of 
reaction to specific antibody (Sawai et al).  
(ii) In 1973, the Richmond and Sykes scheme classified the enzymes into five 
main divisions based on the substrate profile and the gene coding for β-
lactamase. 
(iii) In 1989, Bush scheme classified β-lactamase on the basis of molecular 
structure and the substrate inhibition. 
(iv) In 1980, Ambler was the first to propose the Molecular structure 
classifications. 
(v) More recently, Bush, Jacoby, and Medeiros devised a classification scheme 
based on the sequence of nucleotide on the genes for placing β-lactamases 
into functional groups and on the enzyme’s biochemical properties and 
molecular structure59. 
 
 
 
 
 (Classification schemes for bacterial b-lactamases) 
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- 
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a Csase, cephalosporinase; PCase, penicillinase; CXase, cefuroxime-
hydrolyzing b-lactamase. 
b CA, clavulanic acid. 
c ND, not determined. 
 
EXTENDED SPECTRUM BETA LACTAMASES (ESBL) 
 
 ESBL are plasmid mediated betalactamases that produce resistance to broad 
spectrum betalactam antibiotics like 3rd and 4th generation cephalosporins, extended 
spectrum penicillin, Aztreonam60.  
 
 
METHODS FOR DETECTION OF EXTENDED SPECTRUM BETA 
LACTAMASES61,62 
SCREENING OF ESBL-Disc Diffusion method52,63 
The disc diffusion methods are the screening test for ESBL production by 
Escherichia coli, Klebsiella and Proteus mirabilis as proposed by CLSI 2015 
guindelines  use cefotaxime, ceftazidime, cefpodoxime, ceftriaxone and astreonam 
for the screening of ESBL production. Screening test is positive for ESBL is that the 
isolates showing resistant to 2 or more 3rd generation cephalosporin and it should be 
confirmed by phenotypic confirmatory test. The resistant zone size for ESBL as per 
CLSI 2015 guidelines: Cefotaxime ≤ 27mm, Ceftazidime ≤ 22mm, Ceftriaxone  ≤ 
27mm, Cefpodoxime  ≤ 17mm and Aztreonam  ≤ 27mm respectively. 
CONFIRMATORY TEST FOR ESBL: 
1. Phenotypic confirmatory disc diffusion test11,52,64 
 The CLSI advocates the phenotypic confirmatory test for the detection of 
production of ESBL by Klebsiella and Escherichia coli which use the cefotaxime or 
ceftazidime discs (30μg) with or without clavulanate (10μg). A Semiconfluent 
growth of test organism on Mueller Hinton agar shows difference of 5 mm along 
the cephalosporin with clavulanate disc compared to cephalosporin disc alone. 
2.Minimum Inhibitory Concentration 
 Agar dilution method : 
Minimum inhibitory concentration was performed by agar dilution method 
Various concentration of third generation cephalosporins like cefotaxime or 
 
 
ceftazidime 2μg to 2048μg/ml and cephalosporin with 4μg of clavulanic acid 
ranging from 0.5μg to 2048μg/ml of agar was tested with isolates. MIC is the least 
concentration at which there is no visible growth and it was obtained as eight fold 
decrease in CAZ-CL compared to ceftazidime. 
 
 Broth Micro dilution: 
 Disc potentiation test can also be done using broth microdilution assays by 
using ceftazidime (0.25to128μg/ml), ceftazidime with clavulanate (0.25/4 to128/4 
μg/ml), cefotaxime (0.25 to64μg/ml), and cefotaxime with clavulanate (0.25/4 to 
64/4 μg/ml) decrease in MIC of two fold serial dilution of cephalosporin with 
clavulanate compared to the MIC of cephalosporin alone suggests positive for 
ESBL production. 
COMMERCIAL METHODS AVAILABLE TO DETECT ESBL 
(i)        Epsilometer-Test for ESBLs65,66 
Plastic drug impregnated strips are produced by AB bio disk in which one 
end contains a gradient of ceftazidime (MIC test ranges from 0.5μg - 32μg/ml) and 
with a ceftazidime gradient and constant concentration of clavulanate (4μg/ml). As 
per CLSI guidelines 2015, MIC value of ceftazidime – clavulanate should be ≥ 8 
fold decrease in concentration than MIC value of ceftazidime alone.  
(ii)  Vitek ESBL67 
Vitek ESBL cards contain cefotaxime and ceftazidme alone and 
cephalosporin plus constant concentration of clavulanate. Cards are inoculated in 
the same manner as that for regular vitek cards. Cards are analysed automatically as 
 
 
soon as the growth in the control well has attained a set threshold. A prefixed 
reduction in the growth of cefotaxime and ceftazidime plus clavulanic acid 
containing wells is compared with the growth in the wells having 
cefotaxime/ceftazidime alone, indicates positive for ESBL producer. The sensitivity 
and specificity of the test is more than 90%. 
GENOTYPIC METHOD TO DETECT ESBL67,68,69: 
 Detection of the common ESBL gene such as TEM, SHV and CTX-M by 
molecular method10,68. 
Test Advantages Disadvantages 
DNA 
Probes 
Specific for gene family(e.g., 
TEM or SHV) 
Labour intensive, cannot 
distinguish between ESBLs and 
non ESBLs, and between 
variants of TEM or SHV 
PCR Easy to perform, specific for 
gene family(e.g.,TEM or SHV) 
Require technical skill and 
expensive. 
Oligotyping Detects specific TEM variants Requires specific 
oligonucleotide probes, labour 
intensive, cannot detect new 
variants. 
PCR- 
RFLP 
Easy to perform, can detect 
specific nucleotide changes  
Nucleotide changes must result 
in altered restriction site for 
detection. 
Nucleotide 
sequencing 
Gold standard, can detect all 
variants 
Labour intensive, can be 
technically challenging, can be 
difficult to interpret manually. 
Real Time 
PCR 
Rapid identification, minimum 
cross contamination 
Expensive, technical skill 
required 
 
 
 
METALLOBETALACTAMAES70: 
Metallo-β-lactamases (MBL’s) are carbapenemases produced mainly by 
Pseudomonas aeruginosa which require zinc at the site of action. They are 
designated in Ambler’s Class B and Bush-Jacoby Medeiros Group 3. They 
hydrolyze virtually all β-lactam agents such as penicillin, cephalosporin, including 
the carbapenams. 
Till now seven major types of MBL were described worldwide – IMP, SPM, 
VIM, GIM, SIM, AIM-1 and NDM-1. Among them, blaIMP and blaVIM are the 
most common types of MBLs that are prevalent worldwide. From India, only 
blaVIM and NDM-1 have been reported in P. aeruginosa in the past.  
TESTS TO DETERMINE METALLO BETA LACTAMASES AMONG NON 
FERMENTERS 
SCREENING FOR MBL 
An isolate of P. aeruginosa was considered screen-test positive for MBL 
when it was Imipenem resistant: 10 μg(IPM) and/or Meropemem: 10 μg (MRP) 
and/or Ceftazidime: 30 μg (CAZ) . Antibiotic sensitivity was done by the Kirby-
Bauer disc diffusion method as per CLSI recommendation. 
CONFIRMATION OF MBL PRODUCTION 
MODIFIED HODGE TEST71: 
MHA plate is streaked with the ATCC Escherichia coli 25922 and an 
imipenem disc is placed in the centre. Imipenem resistant isolates are inoculated 
from the edge of the disc to the periphery of the plate. It is incubated overnight and 
 
 
read. Imipenem hydrolyzing strains produce distortion on the zone whereas non 
hydrolyzing zones do not produce any effect. 
Amp C BETALACTAMASES72 
METHODS TO DETECT Amp C PRODUCTION73  
 All Enterobacteriaceae isolates were screened for Amp C betalactamases 
production by disk diffusion method. 
SCREENING OF Amp C PRODUCTION74,75: 
All isolates were screened for cefoxitin  susceptibility and those which had a  
zone diameter of ≤ 18 mm were suspected to be AmpC producers. 
Amp C DISK TEST7,70,76 : 
 In a MHA plate, a lawn culture of E. coli ATCC 25922 was made. Sterile 
saline (20μl) was put on the sterile disks (6 mm) which was later inoculated with 
several colonies of test organism. Cefoxitin 30µg disk (almost touching) was placed 
on a fresh inoculated plate. The inoculated disk was then placed adjacent to 
cefoxitin disk and incubated overnight at 35°C. The inference was made as follows: 
  Flattening or indentation of the cefoxitin inhibition zone in the vicinity of the 
test disk was taken as positive. A negative test had an undistorted zone. 
 
MANAGEMENT OF INFECTION WITH ESBL – PRODUCING 
ORGANISMS60,77 
 ESBL producers are treated with Piperacillin – Tazobactam ,Cefoperazone – 
sulbactam in case of mild infection ,whereas severe infection are treated  with 
Carbapenems (Ertapenem, Meropenem, Imipenem).  
 
 
        Amp C producers are usually resistant to cephamycins and oxyimino-beta 
lactams but they are sensitive to carbapenams but diminished porin expression 
makes them resistant to carbapenam as well which can be treated with Polymixins, 
Tigecycline, Fosfomycin or Colistin. 
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS48,78 
Staphylococcus aureus is the most important human pathogen present in the 
external environment and in the anterior nares of 20- 40% of adults. It is also seen 
in the axillae, intertriginous skin folds, the perineum, and the vagina. It is 
responsible for mild infections to severe life threatening infections. Penicillin was 
the drug of choice for the treatment of serious S.aureus infections. The advent of 
penicillin resistance in the S.aureus was due to the acquisition of plasmid borne 
genetic elements coding for β lactamase production. Later, Penicillinase-resistant, 
semisynthetic penicillins such as oxacillin, methicillin was the drug of choice due to 
its incorrect use, MRSA showing difference in penicillin binding protein known as 
PBP2a from a chromosomal gene (mecA) has emerged. Initially1970s MRSA was 
accounting to 40-60% of all nosocomial infection but after 1990 it has been 
associated with population in the community who has no contact with hospital 
known as community- associated MRSA (CA-MRSA) strains which has caused 
death of 4 children due to necrotizing pneumonia79. MRSA prevalence in India has 
increased from 12% (1992) to 40% (2009)12. 
 
 
 
 
MECHANISM OF RESISTANCE 
The chromosomally localized mecA gene responsible for methicillin 
resistance acts by synthesizing Penicillin binding protein 2a in turn downregulates 
the cross linking of peptidoglycan layer, through which it shows resistance to 
betalactam antibiotics. Four different SCC mec elements have been recognized. 
SCCmec type I, II and III is associated with Health care associated MRSA (HA-
MRSA).  Community associated MRSA tend to carry SCC Type IV element and 
Panton- Valentine leukocidin as virulence factor. 
METHODS TO DETECT MRSA 
PHENOTYPIC METHOD 
1. Cefoxitin disc diffusion test12,76-  
 The test was performed by placing 30μg of Cefoxitin disc in the Mueller 
Hinton Agar plate inoculated with test organism. The plate was kept in incubator at 
a temperature of 37˚C. The zone of inhibition was determined after 24 hrs and the 
zone size was interpreted as Susceptible  ≥ 22mm and Resistant  ≤ 21 mm. 
2. Oxacillin screen agar method80 
 Oxacillin screening is done by using 6 µg/ml of oxacillin in Mueller Hinton 
agar to confirm all methicillin resistant strains .The strains which grow in this 
medium is considered as methicillin resistant Staphylococcus aureus (MRSA). 
 
 
 
 
 
3. MIC determination 
(i) Agar dilution method 
4-5 discrete colonies were emulsified onto 4-5 ml of nutrient broth which is 
adjusted to 0.5 McFarlands standard.0.0001ml is used as the final inoculum. The 
concentration of oxacillin used is 32μg-0.015μg/ml. After drying,1μl of inoculum is 
inoculated in the plates using a calibrated loop . The plates are incubated at 37˚C for 
24hrs.MIC is the lowest concentration at which no visible growth occurs. 
Susceptible - ≤ 2μg/ml, Resistant - ≥ 4μg/ml 
(ii) Broth dilution method 
To a Mueller Hinton broth with 4% NaCl, serial dilution of oxacillin is 
added. Few colonies of S. aureus are emulsified into fresh peptone water and 
adjusted to match 0.5 McFarlands standard which is used as inoculum. It is 
incubated at 33-35c or 24 hrs. Oxacillin MIC <2μg/ml sensitive and Resistant> 
2μg/ml. 
(iii) E-TEST12,52,81: 
 MIC test should be performed to differentiate Vancomycin susceptible 
isolates of S.aureus from Vancomycin intermediate isolates. Plastic drug 
impregnated strips are produced by in which a gradient concentration of  
Vancomycin (MIC test ranges from 0.016μg - 256μg/ml) was applied on a MHA 
plate on which MRSA isolates were swabbed and the plates were incubated at 37ºC 
overnight. Interpretation of Vancomycin MIC E-test for MRSA as per CLSI  
guidelines 2015 are as  follows 52: <2 µg/ml is sensitive,4-8 µg/ml is Intermediate  
and  ≥16 µg/ml is Resistant. 
 
 
 GENOTYPIC METHODS 82 
Multiplex PCR for MRSA detection of mec A and fem B genes, coag genes, 
ccr genes, nuc genes, toxin genes. 
1. Pulsed Field Gel Electrophoresis 
From an overnight grown culture of a single colony, a bacterial pellet is 
processed and the restriction fragments are separated on the gel. Gel is stained with 
ethidium bromide. The photo is taken under Ultra Violet light. Strain relatedness 
among CA-MRSA and HA-MRSA isolates can be investigated. 
2. Real time PCR 
MRSA isolates are detected directly from blood culture bottles using real 
time PCR assays.  Based on melting curve analysis, the assay differentiates into 
clusters. 
3. Multi locus Sequence Typing (MLST) 
The clonal evaluation of MRSA is detected by MLST.  Sequential analysis 
from 7 Staphylococcus aureus shows the housekeeping genes as follows i.e., aroE, 
arcC, glpF, gmK, pt, tpi and yqil. Each isolate is defined by all the alleles of the 
seven genes. This results in an allele profile / gene sequence type (ST). 
4. Microarray Analysis 
Multiplex PCR products can be used as hybridization samples. After 
hybridization at the test site of the microarray, detection of fluorescence is done 
automatically by the instrument images of the array. Automatically captured image 
is then analysed using the image analysis software of the instrument. 
 
 
Management of MRSA infections60, 77 
The drug of choice for serious infections caused by Methicillin Resistant 
Staphylococcus aureus is glycopeptide antibiotics (Vancomycin or Teicoplanin). 
PREVENTION:  
VACCINATION2, 31, 83, 84, 85 :  
 Vaccination against influenza, pneumococcus, Haemophilus influenza b is 
used to reduce the burden of pneumonia. 
1. Influenza vaccines are of two types intranasal live-attenuated cold-adapted 
vaccine (not indicated in immunocompromised patients) and intramuscular 
inactivated vaccine. During an influenza outbreak, vaccination given immediately 
with chemoprophylaxis (zanamivir or oseltamivir for 2 weeks).Efficacy is about it 
prevents 53% pneumonia, 50% from hospitalization and 68% from death. 
2. Pneumococcus- Pneumococcal infection severe due to its invasive property 
and drug resistance. two types of pneumococcal vaccine - PPV23 pneumococcal 
polysaccharide vaccine contains capsular material from 23 pneumococcal 
serotypes  and PCV13, protein conjugate pneumococcal vaccine contain capsular 
polysaccharide from 13 protein commonly affecting children. PCV13has an 
immunogenic protein which induces the production of T cell–dependent antigens 
for long-term immunologic memory. PCV13 vaccine is given for children, 
immunocompromised patients and elderly. VAP-oral care, hand hygiene, use of 
prophylactic agent of gastric ulcer, gloves usage, protocol directed weaning 
procedure, change of humidifier weekly and suction system for each patient9.
 
 
MATERIALS AND METHODOLOGY 
 
 The study of bacterial isolates causing Pneumonia in 205 adult patients with 
suspected Pneumonia includes 150 Community Acquired Pneumonia (CAP), 30 
Hospital Acquired Pneumonia (HAP) and 25 Ventilator Associated Pneumonia 
(VAP). 
STUDY DESIGN :  Cross sectional study 
STUDY PERIOD :  January 2015 to June 2016 
STUDY PLACE  :  Government Kilpauk Medical College and Hospital, Chennai. 
  
INCLUSION CRITERIA 
1. Clinically suspected and radiologically proven cases of pneumonia. 
2. Patient above 18 years of age (adult). 
EXCLUSION CRITERIA: 
1. Patient with active tuberculous leision was excluded. 
2. Patient taking antibiotics currently and past for the period of about two 
weeks were excluded. 
SAMPLE COLLECTION, TRANSPORT AND PROCESSING: 
 Totally 205  respiratory samples from Pneumonia in adult  patients attending 
Government Kilpauk Medical College and Hospital includes  150 sputum samples 
from Community Acquired Pneumonia(CAP), 30 sputum samples from Hospital 
Acquired Pneumonia(HAP) and 25 Endotracheal samples from Ventilator 
Associated Pneumonia(VAP).  
 
 
 Blood samples was collected from pneumonia patients having symptoms of 
fever (Temp ≥37.8ºC )86 were  included 80 samples from CAP, 12  samples from 
HAP and  25 samples from VAP. 
 After obtaining informed consent from these patients respiratory samples 
and blood were collected under sterile precaution and transported immediately to 
the laboratory in appropriate settings and sample processing done. 
SAMPLE COLLECTION 46, 87: 
1.  Sputum – expectorated or induced41,3,28 
Deeply coughed out or when the sputum is scanty it was induced  with saline 
nebulisation  and was collected in a disposable leak proof  sterile ,wide mouthed 
container with tight fitting lid after giving proper instruction to the patient.  
2. Endo Tracheal aspirate (ETA)6,45 
 Endo Tracheal aspirate (ETA) was collected from the patients who have 
been in mechanical ventilation for more than fourty eight hours with suspected 
VAP. One milliliter of  ETA  was collected in a sterile screw capped plastic 
container  by using twenty two inch Ramson’s  12 F suction catheter with a mucus 
extractor which  was introduced slowly in to the endotracheal tube for about a 
distance of twenty five to twenty six centimeter. 
3. Blood86: 
 Blood culture was performed in all cases of suspected Pneumonia with fever 
(temp.≥37.8ºC) prior to starting antibiotics.  Under aseptic precaution, 5 ml of 
blood was collected by venipuncture using sterile syringe and transferred after 
removing the needle into the blood culture bottle containing 50 ml (1:10 
 
 
dilution)45of Brain heart infusion broth. Samples collected were sent immediately to 
Microbiology laboratory without delay.  
SAMPLE PROCESSING 
a) Macroscopic examination41: 
 The sputum was examined for colour (rusty, red currant jelly was noted), 
consistency, purulent/non purulent to distinguish it from saliva. 
b) Direct Microscopy: 
The Sputum, Endotracheal aspirate specimens were subjected to the following 
microscopic examination using standard laboratory techniques. Gram staining was 
done and examined for the presence of relative number of polymorphonuclear cells 
and squamous epithelial cells. 
 
Criteria for assessing the quality of respiratory samples48: 
Bartlett’s grading: 
Number of 
neutrophil 
(lpf) 
Grade 
 <10 0 
10 - 25 +1 
>25 +2 
Presence of 
mucus 
+1 
 
Number of 
epithelial 
cells 
Grade 
10 - 25 -1 
>25 -2 
 
 
 Total number of polymorphonuclear cells and epithelial cells and in 20-30 
LPFs was calculated and averaged the total score was arrived. A final score of 0 or 
less indicated lack of active inflammation or contamination, and a score of 1 and 
above was considered an acceptable sample. Presence of  >25 PMN cells with  less 
 
 
than ten squamous epithelial cells per low power field in Gram stained smear of  
ETA samples was accepted for culture 6. 
CULTURE 4: 
Sputum culture: 
 Sputum samples were then plated into the following agar media: Nutrient 
agar 5% Sheep blood agar, Chocolate agar and MacConkey agar. All cultures were 
incubated at 37°C under aerobic condition and addition to this blood agar and 
Chocolate agar plates were kept under 5-10% carbon dioxide atmosphere. Plates 
were evaluated for growth at 24 and 48hours. 
Endotracheal aspirate culture: 
 Endotracheal aspirate specimens were subjected to quantitative culture 6,88,89. 
Colony count of ≥105 cfu/ml was consistent with pathogen and not a colonizer7,8. 
 Endotracheal aspirate sample was resuspended in the fluid and three serial 
dilutions were made (1/10, 1/100, 1/1000). Of these 0.01 ml from 1/1000 dilutions 
was plated on to Blood agar. The number of bacteria in culture of ETA samples 
were expressed in colony-forming unit (cfu) per milliliter.(cfu/ml = number of 
colonies ×dilution factor ×inoculation factor)Presence of single colony in 0.01ml of 
1/1000 dilution indicate ≥105 colonies49 .  Bacterial isolates grown in culture were 
identified by means of Gram’s staining and biochemical reactions by standard 
microbiological techniques. 
Blood culture45,48: 
 The inoculated  blood culture bottles were incubated at 37°C and examined 
after 18 to 24 hours for any turbidity, discoloration or clotting. The first subculture 
 
 
was done onto Nutrient agar, blood agar and Macconkey agar plates and incubated 
at  37°C for 18 to 24 hours, meanwhile in addition to these blood agar plate was 
kept under 5-10%CO2. These bottles were reincubated and checked for turbidity 
twice daily.  
ANTIBIOTIC SUSCEPTIBILITY TESTING52 
Antibiotic sensitivity testing was done on Mueller Hinton agar using Kirby 
Bauer disk diffusion method. Interpretation of the results was done by measuring 
the sizes of the zone of inhibition according to CLSI guidelines 2015(M-100-
S25).Quality control strains used are as follows7:ATCC 25922  Escherichia coli ,  
ATCC 27853 Pseudomonas aeruginosa   and ATCC 25923   Staphylococcus 
aureus  .            
DETECTION OF  EXTENDED SPECTRUM BETA LACTAMASES 
 All Enterobacteriaceae isolates were screened for betalactamases production 
by disk diffusion method and confirmed by phenotypic confirmatory disc diffusion 
test. 
Disk diffusion methods-screening for ESBL52: 
Disk diffusion test was done for all Enterobacteriaceae isolates against 
Cefotaxime (30 μg), Ceftriaxone (30 μg), and Ceftazidime (30 μg) antibiotic disks 
for the screening of the isolates for potential ESBL production. 
 Overnight incubation was done at 37˚C after which the zone size was read as 
per CLSI recommendations for ESBL screening criteria in which the isolates 
showed resistant to two or more 3rd generation Cephalosporins90.                        
 
 
Antibiotics Zone of inhibition – 
interpretation 
 Cefotaxime (30µg) ≤27mm 
Ceftriaxone(30µg) ≤25mm 
Ceftazidime(30µg) ≤22mm 
 
Quality controls were performed using 
          ATCC 700603 Klebsiella pneumoniae  - Positive control. 
Phenotypic confirmatory disc diffusion test11,52 
This test was done for all Enterobacteriaceae isolates against Ceftazidime 
(30 μg) antibiotic discs with and without clavulanic acid (10 μg). These discs were 
placed on a Mueller –Hinton agar plate inoculated with bacterial suspension 
equivalent to 0.5 McFarland standards. Overnight incubation was done at 37°C 
after which the result was interpreted as follows: 
If the zone diameter of Ceftazidime with clavulanic acid was increased ≥ 5 
mm when compared with Ceftazidime alone was taken as positive for ESBL 
production. 
MIC determination – E Test method65 
 Minimum inhibitory concentration was calculated for all isolates of ESBL by 
Epsilometer test. 
 
 
 
 
Epsilometer-Test for ESBL 10,52 
 Plastic drug impregnated strips are produced by Himedia in which one end 
contains a gradient of ceftazidime (MIC test ranges from 0.5μg - 32μg/ml) and 
Ceftazidime+clavulanic acid (MIC test ranges from 0.064 μg - 4μg/ml) on the other 
end was applied on a MHA plate on which ESBL isolates are swabbed. The plates 
were incubated at 37ºC overnight. 
 As per CLSI guidelines 2015, MIC value of ceftazidime – clavulanate 
should be ≥ 8 fold decrease in concentration than MIC value of ceftazidime alone. 
(Manufacturer recommends MIC value in the ratio of CAZ:CAC  ≥ 8). 
 
DETECTION OF ESBL PRODUCERS BY POLYMERASE CHAIN 
REACTION (PCR) 10  
DNA Extraction methods 
DNA extraction was done with the help of DNA Purification kit (PureFast 
Bacterial Genomic DNA purification kit) and polymerase chain reaction master 
mix. 
 Constituents of Master Mix 2X  
Taq DNA Polymerase - 2Units. 
10X Taq reaction buffer 
2mM Magnesium Chloride. 
10mMdNTPs mix - 1μl. 
Polymerase Chain Reaction additives. 
 
 
Agarose for the purpose of Gel Electrophoresis - Agarose, 50XTAE buffer, 
6Xgel loading buffer, Ethidium bromide were used. 
PRIMERS 
CTX-M primer( Product size - 269bp ) 
           5'-TTATGCGCAGACGAGTGCGGTG-3'  
5'-TCACCGCGATAAAGCACCTGCG-3' 
SHV primer(Product size- 276bp ) 
5'-CGCCGCCATTACCATGAGCGAT-3'  
 
5'-ACCCGATCGTCCACCATCCACT-3' 
TEM primer(Product size - 250bp)  
5’-CCAAACGACGAGCGTGACACCA-3’  
 
5’-AGCGCAGAAGTGGTCCTGCAAC-3’ 
Procedure of DNA Extraction 
 One ml of overnight culture of  Klebsiella pneumoniae was centrifuged at 
6000 rpm for five minutes and supernatant was discarded.Pellet was suspended in 
200μl of Phosphate Buffer Saline (PBS). 
 To the suspension twenty microlitre of lysozyme(10mg/ml) , 180μl of 
lysozyme digestion buffer was added and incubated at 37ºC for fifteen minutes. 
Mixing with 400μl of binding buffer ,5 μl of internal control template and 20 μl of 
Protienase K was done by inverting the tube several times and then incubated at 
56ºC for 15 minutes. 
 
 
 300μl of ethanol was added and mixed well. Whole lysate was transferred 
into Pure Fast spin column. It was then centrifuged for one minute at 10000 rpm. 
Discard flow through and 500μl of Wash Buffer-1 was added and centrifuged 
at 10000 rpm for 1Minute. Discard flow through and 500μl of Wash Buffer-2 was 
added and centrifuged at10000 rpm for 1minute. This procedure was done for two 
times. 
 Discard flow through centrifuged column for 1 more minutes so that any 
residual ethanol will be removed. The content in spin column was transferred to a 
1.5 ml micro-centrifuge tube. 100μl of Elution Buffer was added to elute the DNA, 
and centrifuged for 2 minute. 
 
Procedure of Polymerase Chain Reaction 
1. Reaction was done with the components in PCR vial-10μl of  Master 
Mix, 5μl Genomic DNA, 5μl Primer mix which constitutes about 20 ml 
of  total volume. 
2. All these were mixed gently and spinned down briefly. 
3. They were then placed in the PCR machine and programmed; 
Initial Denaturation: 95ºC for 5 minutes 
Denaturation: 94ºC for 30seconds in cycles of 35 
Annealing: 58ºC for 30 seconds in cycles of 35 
Extension: 72ºC for 30 seconds in cycles of 35 
Final extension: 72º C for 5 minutes 
 
 
 
 
Method to perform Agarose gel electrophoresis: 
 2gm agarose was mixed in 100ml of 1X TAE buffer; it was melted by 
heating in a micro oven. 
 When the temperature of agarose gel was about 60ºC, Ethidium bromide 
(5μl) was added. 
 Into the gel platform warm agarose solution was added slowly. 
 Till the agarose got solidified it was kept undisturbed. 
 Into the submarine gel tank1XTAE buffer was added. 
 Gel platform was kept into tank without any disturbance. The tank buffer 
level 
was kept maintaining upto 0.5cm above the gel. 
 Polymerase Chain Reaction samples were loaded after mixing with gel 
loading 
dye and 10μl HELINI 100bp DNA Ladder. 
 Electrophoresis was done at 50V till the dye reaches 3/4th distance of the 
agarose gel. The Agarose gel was seen with UV Transilluminator, the pattern 
of the bands were seen and interpreted. 
DETECTION OF METALLOBETALACTAMASE PRODUCERS7: 
Meropenem: 10μg (MRP) (Zone of inhibition ≤18mm) resistant 
Pseudomonas aeruginosa isolates were taken for screening  MBL production.   
Antibiotic sensitivity testing was done by the Kirby-Bauer disc diffusion method. 
 
 
 
METHODS TO DETECT AmpC PRODUCTION73 
 All Enterobacteriaceae isolates were screened for AmpC betalactamases 
production by disk diffusion method. 
SCREENING OF AmpC PRODUCTION: 
All isolates were screened for cefoxitin (30µg) susceptibility and those 
which had a  zone diameter of ≤ 18 mm were suspected to be AmpC producers74. 
AmpC DISK TEST7,6,70,76 : 
 In a MHA plate, a lawn culture of E. coli ATCC 25922 was made. Sterile 
saline (20μl) was put on the sterile disks (6 mm) which was later inoculated with 
several colonies of test organism. Cefoxitin30µg disk (almost touching) was placed 
on a fresh inoculated plate. The inoculated disk was then placed adjacent to 
cefoxitin disk and incubated overnight at 35°C. The inference was made as follows: 
 Flattening or indentation of the cefoxitin inhibition zone in the vicinity of the test 
disk  was taken as positive. A negative test had an undistorted zone. 
 
TESTS TO DETECT METHICILLIN RESISTANT STAPHYLOCOCCUS 
AUREUS(MRSA)12 
 All isolates of Staphylococcus aureus were screened for MRSA by disk 
diffusion method and confirmation done by genotypic method. 
 
 
 
 
CEFOXITIN DISC DIFFUSION TEST 
The test was performed by placing 30μg of Cefoxitin disc in the Mueller 
Hinton Agar plate inoculated with test organism. The plate was kept in incubator at 
a temperature of 37˚C. The zone of inhibition was determined after 24 hrs and the 
zone size was interpreted as Susceptible ≥ 22mm & Resistant ≤ 21 mm. 
VANCOMYCIN E-TEST12,52: 
 
 MIC test was performed to differentiate Vancomycin susceptible isolates of 
S.aureus from Vancomycin intermediate isolates. Plastic drug impregnated strips 
are produced by in which a gradient concentration of Vancomycin (MIC test ranges 
from 0.016μg - 256μg/ml) was applied on a MHA plate on which MRSA isolates 
were swabbed and the plates were incubated at 37ºC overnight. Interpretation of 
Vancomycin MIC E-test for MRSA as per CLSI guidelines 2015 are as follows52: 
        Vancomycin concentration                 Interpretation 
        < 2 µg/ml                                                  Sensitive 
         4-8 µg/ml                                                Intermediate    
          ≥16 µg/ml                                              Resistant 
 
 
 
 
 
 
 
 
 
 
 
Detection of mec A gene in MRSA isolates by polymerase chain reaction (PCR)  
DNA Extraction methods 
DNA extraction was done with the help of DNA Purification kit (PureFast 
Bacterial Genomic DNA purification kit) and polymerase chain reaction master 
mix. Constituents of Master Mix 2X -10X Taq reaction buffer,Taq DNA 
Polymerase - 2Units, 10mMdNTPs mix - 1μl , 2mM Magnesium Chloride. 
10mMdNTPs mix - 1μl. 
Agarose for the purpose of Gel Electrophoresis - Agarose, 50XTAE 
buffer,6Xgel loading buffer, Ethidium bromide were used. mec A gene primer mix-
5μl/reaction .PCR product – 220bp. 
Forward primer  5-TGGCTATCGTGTCACAATCG-3 
Reverse primer 5-CTGGAACTTGTTGAGCAGAG-3 
 
Procedure of DNA Extraction 
 One ml of overnight culture of Staphylococcus aureus was centrifuged at 
6000 rpm for five minutes and supernatant was discarded. Pellet was suspended in 
200μl of Phosphate Buffer Saline (PBS). 
 To the suspension twenty microlitre of lysozyme(10mg/ml) , 180μl of 
lysozyme digestion buffer was added and incubated at 37ºC for fifteen minutes. 
Mixing with 400μl of binding buffer ,5 μl of internal control template and 20 μl of 
Protienase K was done by inverting the tube several times and then incubated at 
56ºC for 15 minutes. 300μl of ethanol was added and mixed well. Whole lysate was 
 
 
transferred into Pure Fast spin column. It was then centrifuged for one minute at 
10000 rpm. Discard flow through and 500μl of Wash Buffer-1 was added and 
centrifuged at 10000 rpm for 1Minute.Discard flow through and 500μl of Wash 
Buffer-2 was added and centrifuged at10000 rpm for 1minute. This procedure was 
done for two times. 
 Discard flow through centrifuged column for 1 more minutes so that any 
residual ethanol will be removed. The content in spin column was transferred to a 
1.5 ml micro-centrifuge tube.100μl of Elution Buffer was added to elute the DNA, 
and centrifuged for 2 minutes. 
 
Procedure of Polymerase Chain Reaction 
1. Reaction was done with the components in PCR vial-10μl of  Master 
Mix, 5μl Genomic DNA, 5μl Primer mix which constitutes about 20 ml 
of  total volume. 
2. All these were mixed gently and spinned down briefly. 
3. They were then placed in the PCR machine and programmed; 
Initial Denaturation: 95ºC for 5 minutes 
Denaturation: 94ºC for 30seconds in cycles of 35 
Annealing: 58ºC for 30 seconds in cycles of 35 
Extension: 72ºC for 30 seconds in cycles of 35 
Final extension: 72º C for 5 minutes 
 
 
 
 
 
Method to perform Agarose gel electrophoresis: 
 2 gm agarose was mixed in 100ml of 1X TAE buffer; it was melted by 
heating in a micro oven. 
 When the temperature of agarose gel was about 60ºC, Ethidium bromide 
(5μl) was added. 
 Into the gel platform warm agarose solution was added slowly. 
 Till the agarose got solidified it was kept undisturbed. 
 Into the submarine gel tank1XTAE buffer was added. 
 Gel platform was kept into tank without any disturbance. The tank buffer 
level was kept maintaining upto 0.5cm above the gel. 
 Polymerase Chain Reaction samples were loaded after mixing with gel 
loading dye and 10μl HELINI 100bp DNA Ladder. 
 Electrophoresis was done at 50V till the dye reaches 3/4th distance of the 
agarose gel. The Agarose gel was seen with UV Transilluminator, the pattern 
of the bands were seen and interpreted. 
 
 
STATISTICAL ANALYSIS 
                 The test outcome was observed, recorded and analysed. The data that 
were analysed and presented in the form of statistical tables, pie charts and 
histograms if necessary in appropriate places. P values were calculated by Chi –
Square test to compare the proportion between categorical variables. If expected 
 
 
cell frequency is less than five in more than 20% of cells then Fisher’s exact Chi –
Square test is applied. SPSS (Stastical package for the social science) version 22.0 
is used to analyse the data. Significance level is fixed as 5% (α=0.005). The 
significant findings was further discussed in detail and compared with other similar 
studies published in reputed scientific journals. The clinical application of these 
findings will be stressed for better patient care. 
 
  
 
 
RESULTS 
Patients with clinical symptoms and radiological evidence of pneumonia 
attending  medicine OPD and those admitted in IMCU and other wards at 
Government Kilpauk Medical College and Hospital, Chennai were studied for the   
profile of microorganisms isolated by culture with their Antibiotic sensitivity 
pattern. Resistant isolates were studied for Extended Spectrum BetaLactamases 
(ESBL), Metallobetalactamases (MBL), Amp C betalactamases and Methicillin 
Resistant Staphylococcus aureus (MRSA) . The study was done between January 
2015 to June 2016. 205 patients with pneumonia, of which patients with 
Community acquired pneumonia (CAP) (150), Hospital acquired pneumonia (HAP) 
(30) and Ventilator associated pneumonia (VAP)  (25) were studied. The 
observations were recorded and analysed. The results were as follows: 
TABLE NO: 1 AGE WISE DISTRIBUTION IN PNEUMONIA (n=205). 
AGE 
(YEARS) 
CAP 
(n=150) 
HAP 
(n=30) 
VAP 
(n=25) 
20-40 27(18%) 7(23.33%) 2(8%) 
40-60 70(46.66%) 10(33.33%) 14(56%) 
>60 53(35.33%) 13(43.33%) 9(36%) 
 
 As per Table no.1, Patients in the age group of 40-60 years were highly 
affected by CAP and VAP showing CAP 70(46.66%) and VAP 14(56%). In HAP, 
patients in the age group of above 60 years were mostly affected with 13(43.33%). 
 
 
TABLE NO:  2 – GENDER WISE DISTRIBUTION IN PNEUMONIA 
(n=205).  
GENDER CAP(n=150) HAP(n=30) VAP(n=25) 
Males 102(68%) 20(66.66%) 16(64%) 
Females 48(32%) 10(33.33%) 9(36%) 
 
As per Table no.2, adult males were more commonly affected by pneumonia than  
Females, CAP 102(68%), HAP 20 (66.66%) and VAP 16 ( 64%). 
 
TABLE NO: 3 – RISK FACTORS OF PATIENTS WITH 
PNEUMONIA(n=205) 
Risk Factors CAP (n=150) HAP(n=30) VAP(n=25) 
Smoking 73(48.66%) 16(53.33%) 18(72%) 
Diabetes mellitus 58(38.66%) 14(46.66%) 14(56%) 
Chronic obstructive airway 
disease 
33(22%) 8(26.66%) 6(24%) 
Alcoholism 28(18.66%) 13(43.33%) 13(52%) 
As per Table no.3, Smoking is the most common risk factor in CAP 73(48.66%)  
followed by diabetes, COPD and alcoholism  
  
 
 
TABLE NO: 4 - SYMPTOMS OF PATIENTS WITH CAP AND HAP 
Symptoms CAP(n=150) HAP(n=30) 
Cough 142(94.66%) 26(86.66%) 
Fever (temp >37.8ºC) 80(53.33%) 12(40%) 
Breathlessness 53(35.33%) 14(46.66%) 
Chest pain 28(18.66%) 9(30%) 
  
 As per Table no.4, Cough was the most common presenting symptom of 
pneumonia, 142(94.66%) in CAP and 26(86.66%) in HAP followed by fever, 
breathlessness and chest pain. 
TABLE NO: 5 
CHEST XRAY PATTERN OF PATIENTS WITH PNEUMONIA (n=205) 
LUNG LOBES 
AFFECTED 
CAP (n=150) HAP (n=30) VAP (n=25) 
Right lower lobe 54 (36%) 10 (33.33%) 9 (36%) 
Right middle lobe 26 (17.33%) 6 (20%) 4 (16%) 
Left lower lobe 23 (15.33%) 3 (10%) 3 (12%) 
Both lobes 18 (12%) 8 (26.66%) 6 (24%) 
Right upper lobe 16 (10.6%) 2 (6.66%) 2 (8%) 
Left  upper lobe 13 (8.6%) 1 (3.33%) 1 (4%) 
 As per Table no.5, Right lower lobe was the most commonly involved lung 
lobe seen in Chest radiography of pneumonia patients with 54(36%) in CAP, 
10(33.33%) in HAP and 9(36%) in VAP. 
 
 
TABLE NO: 6  –  SAMPLES COLLECTED FROM PNEUMONIA 
PATIENTS AND THEIR CULTURE GROWTH  
PNEUMONIA SAMPLES CULTURE POSITIVE 
CULTURE 
NEGATIVE 
CAP 
Sputum(n=150) 83(55.33%) 67(44.66%) 
Blood(n=80) 8(10%) 72(90%) 
HAP 
Sputum(n=30) 26(86.66%) 4(13.33%) 
Blood(n=12) 2(16.66%) 10(83.33%) 
VAP 
Endotracheal 
aspirate(n=25) 25(100%) 0 
Blood(n=25) 5(20%) 20(80%) 
 
 As per Table no.6, Respiratory samples collected from pneumonia patients 
showed growth in culture as follows: 83(55.33%) in CAP, 26(86.66%) in HAP and 
25(100%) in VAP. P value is <0.001 and is statistically significant. 
 Blood samples collected from pneumonia patients showed growth in culture 
as follows: 8(10%) in CAP, 2(16.66%) in HAP and 5(20%) in VAP. 
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TABLE NO 7 - DIRECT SMEAR vs. CULTURE IN RESPIRATORY 
SAMPLES OF PNEUMONIA PATIENTS  
CAP  (n=150) 
CULTURE Direct Smear Positive Direct Smear Negative 
Culture Positive 80(53.33%) 3(2%) 
Culture Negative 0 67(44.66%) 
 
HAP  (n=30) 
CULTURE Direct Smear Positive Direct Smear Negative 
Culture Positive 24(80%) 2(6.66%) 
Culture Negative 0 4(13.33%) 
VAP  (n=25) 
CULTURE Direct Smear Positive Direct Smear Negative 
Culture Positive 21(84%) 4(16%) 
Culture Negative 0 0 
 
As per Table no.7, Respiratory samples with direct smear positive showing 
culture positivity are CAP 80(53.33%), HAP 24(80%) and VAP 21(84%). CAP 
3(2%), HAP 2(6.66%) and VAP 4(16%) showed direct smear negative but culture 
was positive. 
 
 
 
TABLE NO: 8 - PURE Vs. MIXED GROWTH IN CULTURE  
ORGANISM CAP (n=83) HAP (n=26) VAP (n=25) 
Monomicrobial 71(85.54%) 20(76.92%) 24(96%) 
Polymicrobial 12(14.45%) 6(23.07%) 1(4%) 
 As per Table no.8, Culture growth from respiratory samples of pneumonia 
patients showed both Monomicrobial and Polymicrobial growth. 
TABLE NO 9- A: GRAM POSITIVE Vs. GRAM NEGATIVE IN CULTURE 
OF RESPIRATORY SAMPLES OF PNEUMONIA PATIENTS 
PNEUMONIA SAMPLES 
GRAM 
NEGATIVE 
BACILLI 
GRAM 
POSITIVE 
COCCI 
TOTAL 
CAP Sputum 68(71.57%) 27(28.42%) 
 
95 
HAP Sputum 24(75%) 8(25%) 
 
32 
VAP 
Endotracheal  
aspirate 20(76.92%) 6(23.07%) 
 
26 
 
 As per Table no. 9- A , Among the organisms isolated from respiratory 
samples of pneumonia patients , Gram negative bacilli is the predominant isolate 
with 68(71.57%)  from CAP, 24(75%)  from HAP and 20(76.92%)  from VAP. 
  
 
 
TABLE NO 9- B: - GRAM POSITIVE Vs. GRAM NEGATIVE IN BLOOD  
                         CULTURE OF PNEUMONIA PATIENTS 
PNEUMONIA 
GRAM 
NEGATIVE 
BACILLI 
GRAM POSITIVE 
COCCI 
TOTAL 
CAP 5(62.50%) 3(37.50%) 8 
HAP 1(50%) 1(50%) 2 
VAP 4(80%) 1(20%) 5 
 
 As per Table no. 9- B, Among the organisms isolated from blood samples of 
pneumonia  patients , Gram negative bacilli is the predominant isolate in  
CAP 5(62.50%) and VAP 4(80%).  
 
TABLE NO: 10- DISTRIBUTION OF ORGANISMS IN RESPIRATORY 
SAMPLES OF PNEUMONIA PATIENTS. 
ORGANISMS 
CAP HAP VAP 
TOTAL 
SPUTUM(n=95) SPUTUM(n=32) ETA(n=26) 
Klebsiella pneumoniae 42 (44.21%) 12 (37.50%) 6(23.07%) 60 
Staphylococcus aureus 19(20%) 4(12.5%) 6(23.07%) 29 
Pseudomonas aeruginosa 12(12.63%) 3(9.37%) 5(19.23%) 20 
Escherichia coli 10(10.52%) 5(15.62%) 4(15.38%) 19 
Acinetobacter baumanii 2(2.10%) 2(6.25%) 5(19.23%) 9 
CONS 6(6.31%) 2(6.25%) 0 8 
Serratia marscesens  2(2.10%) 1(3.12%) 0 3 
Streptococcus 
pneumoniae 2(2.10%) 0 0 2 
Enterococcus faecalis 
0 2(6.25%) 0 2 
Proteus mirabilis 0 1(3.12%) 0 1 
 
 As per Table no.10, Klebsiella pneumoniae is the predominant organism 
grown in respiratory samples of pneumonia patients and their distribution  are as 
follows: 42 (44.21%) in CAP, 12 (37.50%) in HAP, 6(23.07%) in VAP is both  
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Klebsiella pneumonia and Staphylococcus aureus . pvalue <0.035 and is stastically 
significant.Among non fermenters, Pseudomonas aeruginosaand Acinetobacter 
baumanii were grown in culture. Staphylococcus aureus is the predominant Gram 
positive cocci isolated in culture. 
TABLE NO: 11- DISTRIBUTION OF ORGANISMS IN BLOOD SAMPLES 
OF PNEUMONIA PATIENTS. 
ORGANISMS CAP(N=8) HAP(N=2) VAP(N=5) TOTAL 
Klebsiella pneumonia 4 (50%) 1(50%)  3 (60%) 8 
Staphylococcus 
aureus 
2(25%) 1(50%)   1(20%) 4 
Pseudomonas 
aeruginosa 
1(12.50%)  0  1(20%) 2 
CONS 1(12.50%)  0  0(20%) 1 
 
As per Table no.11, Klebsiella pneumoniae is the Predominant organism grown in 
blood samples of pneumonia patients and their distribution are as follows: 4 (50%) 
in CAP and 3(60%) in VAP. 
                                                     
 
 
 
 
 
TABLE NO: 12 –A: ANTIBIOTIC SENSITIVITY OF GRAM NEGATIVE  
ISOLATES  FROM SPUTUM SAMPLES OF CAP. 
Antibiotics Klebsiella 
pneumoniae  
(n=42) 
Pseudomonas 
aeruginosa 
(n=12)  
E.coli 
(n=10) 
Acinetobacter 
baumanii 
(n=2) 
Serratia 
marscesens 
(n=2) 
Amoxycillin 
 
5(11.90%) NT 2 (20%) 0 0 
Amoxycillin -
clavulinic acid 
25(59.52%) 6 (50%) 5 (50%) 1(50%) 2(100%) 
Cotrimoxazole 5 (11.9%) NT 3(30%) 0 0 
Cefoxitin 41(97.61%) 12 (100%) 10(100%) 2(100%) 2(100%) 
Cephalexin 11(26.19%) NT 3(30%) 0 0 
Cefotaxime 28(66.66%) NT 10(100%) 2 (100%) 2(100%) 
Ceftazidime 28(66.66%) 11 (91%) 10(100%) 2 (100%) 2(100%) 
Ceftriaxone 29(69.04%) 11(91%) 10(100%) 2(100%) 2(100%) 
Gentamicin 18(42.85%) 6 (50%) 5(50%) 1(50%) 1(50%) 
Amikacin 26(61.90%) 9(75%) 8(80%) 2(100%) 2(100%) 
Ciprofloxacin 20(47.61%) 7 (58%) 5(50%) 1(50%) 1(50%) 
Ofloxacin 22(52.38%) 9 (75%) 6(60%) 2(100%) 2(100%) 
Piperacillin –
Tazobactam 
41(97.61%)  12 (100%) 10 (100%) 2(100%) 2(100%) 
Imipenem 41(97.61%) 11 (91%) 10 (100%) 2(100%) 2(100%) 
Meropenem 42(100%) 11(91%) 10 (100%) 2(100%) 2(100%) 
 
 As per Table no.12-A, Klebsiella pneumonia showed 100% sensitive to  
Meropenem, 97.61% sensitive to Piperacillin –Tazobactam and Imipenem , 66.66 
% sensitive to  3rd generation Cephalosporins (Cefotaxime , Ceftazidime) and 
Amikacin(61.90%) with least sensitive for Cotrimoxazole (11.90%) and 
Amoxycillin(11.90%). 
 
 
 
 
TABLE NO: 12 –B: ANTIBIOTIC SENSITIVITY OF GRAM NEGATIVE  
ISOLATES  FROM SPUTUM SAMPLES OF HAP. 
Antibiotics 
Klebsiella 
pneumoniae  
(n=12) 
E.coli  
(n=5) 
Pseudomonas 
aeruginosa 
(n=3) 
Acinetobacter 
baumanii 
(n=2) 
Serratia 
marscesens 
(n=1) 
Proteus mirabilis 
(n=1) 
Amoxycillin 1(8.3%) 0 NT 0 0 0 
Amoxycillin -
clavulinic acid 4(33.3%) 2 (40%) 2 (66.6%) 1(50%) 1(100%) 1(100%) 
Cotrimoxazole 2 (16.6%) 1 (20%) NT 0 0 0 
Cefoxitin 10(83.3%) 4 (80%) NT NT 1(100%) 1(100%) 
Cephalexin 0 0 NT 0 0 0 
Cefotaxime 6 (50%) 5(100%) NT NT 1(100%) 1(100%) 
Ceftazidime 6 (50%) 5(100%) 2 (66.6%) 2 (100%) 1(100%) 1(100%) 
Ceftriaxone 6 (50%) 5 (100%) 3 (100%) 2(100%) 1(100%) 1(100%) 
Gentamicin 5 (41.6%) 2 (40%) 1 (33.3%) 1(50%) 1(100%) 0 
Amikacin 6 (50%) 3 (60%) 2 (66.6%) 2(100%) 1(100%) 1(100%) 
Ciprofloxacin 4 (33.3%) 1 (20%) 1 (33.3%) 1(50%) 0 0 
Ofloxacin 6(50%) 3 (60%) 2 (66.6%) 2 (100%) 1(100%) 1(100%) 
Piperacillin –
Tazobactam 11 (91%) 5 (100%) 3 (100%) 2(100%) 1(100%) 1(100%) 
Imipenem 12 (100%) 5(100%) 2 (66.6%) 1(50%) 1(100%) 1(100%) 
Meropenem 12 (100%) 5 (100%) 3 (100%) 2 (100%) 1(100%) 1(100%) 
 
 As per Table no.12-B,  Klebsiella pneumoniae  showed 100% sensitive to 
Imipenem, Meropenem, 91% sensitive to Piperacillin/Tazobactam, 83.30% 
sensitive to cefoxitin, 50% sensitive to  3rd generation Cephalosporins (Cefotaxime , 
Ceftazidime)  and Amikacin with least sensitive for Cotrimoxazole (16.66%), 
Amoxycillin(8.3%) and resistant to cephalexin . 
                                        
 
 
 
TABLE NO: 12 –C: ANTIBIOTIC SENSITIVITY OF GRAM NEGATIVE 
ISOLATES FROM ETA SAMPLES  OF VAP  
Antibiotics Klebsiella 
pneumoniae  
(n=6) 
Acinetobacter 
baumanii  
(n=5) 
Pseudomona
s aeruginosa 
(n=5) 
E.coli 
(n=4) 
Amoxycillin 1 (16.6%) NT NT  0 
Amoxycillin -
clavulinic acid 
2 (33.3%) 0 1 (20%) 1 (25%) 
Cotrimoxazole 0 NT NT  0 
Cefoxitin 5 (83.3%) NT NT 3 (75%) 
Cephalexin 0 NT NT  0 
Cefotaxime 3 (50%) NT NT  3 (75%) 
Ceftazidime 3 (50%) 5 (100%) 3 (60%) 3 (75%) 
Ceftriaxone 3 (50%) 5 (100%) 3 (60%) 3 (75%) 
Gentamicin 1 (16.6%) 2 (40%) 2 (40%) 1 (25%) 
Amikacin 3 (50%) 3 (60%) 3 (60%) 2 (50%) 
Ciprofloxacin 2 (33.3%) 1 (20%) 1 (20%) 1 (25%) 
Ofloxacin 3 (50%) 2 (40%) 3 (60%) 2 (50%) 
Piperacillin –
Tazobactam 
5 (83.3%) 4 (80%) 4 (80%) 4 (100%) 
Imipenem 5 (83.3%) 4 (80%) 3 (60%) 3 (75%) 
Meropenem 6 (100%) 5 (100%) 3 (60%) 4 (100%) 
 
 As per Table no.12-C,  Klebsiella pneumoniae  showed  100% sensitive to 
Meropenem , 83.30% sensitive to Piperacillin –Tazobactam, Imipenem, Cefoxitin, 
50% sensitive to 3rd generation Cephalosporins (Cefotaxime, Ceftazidime), 
Ofloxacin,  Amikacin, with least sensitive to  Gentamicin(16.66%), Amoxycillin 
(16.66%) and resistant to  Cotrimoxazole,  Cephalexin. 
 
 
 
            Pseudomonas aeruginosa showed 80% sensitive to Piperacillin 
Tazobactam, 60% sensitive to Imipenem, Meropenem, 3rd generation 
Cephalosporins (Ceftazidime, Ceftriaxone), Ofloxacin, Amikacin, with least 
sensitive to ciprofloxacin (20%). 
 Acinetobacter baumanii showed 100% sensitive to Meropenem, 3rd 
generation Cephalosporins (Ceftazidime, Ceftriaxone), 80% sensitive to Piperacillin 
–Tazobactam, Imipenem, with least sensitive ciprofloxacin (20%). 
 
TABLE NO: 13 – ANTIBIOTIC SENSITIVITY OF GRAM POSITIVE 
ISOLATES FROM RESPIRATORY SAMPLES OF PNEUMONIA 
PATIENTS.  
Antibiotics 
Staphylococcus aureus Coagulase Negative Staphylococcus aureus 
Streptococcus 
pneumoniae 
Enteroccus  
faecalis 
CAP(n=19) HAP(n=4) VAP(n=6) CAP(n=6) HAP(n=2) CAP(n=2) HAP(n=2) 
Penicillin  G NT  NT  NT NT NT 2(100%) NT 
Amoxycillin 2 (10.5%) 1 (25%) 1 (16.66%) 1 (16.6%) 0  0 0 
Erythromycin 12 (63.15%)   2 (50%)  3(50%) 4 (66.6%) 1 (50%) 2  
(100%) 
1 (50%) 
Doxycycline 13 (68.4%) 3 (75%)  3(50%) 4 (66.6%) 
 
1 (50%)  2 (100%) 2 (100%) 
Co-
trimaxazole 
5 (26.3%) 2 (50%)  1(16.66%) 2 (33.3%) 1 (50% 2  
(100%) 
0 
Cefoxitin  16 (84.2%)  3 (75%) 4 (66.66%) 6 (100%) 2 (100%)  0 0 
Cephalexin 0 0  0 0  0 0  NT  
Cefotaxime 16 (84.20%) 3(75%) 4 (66.66%)
  
6 (100%) 2 (100%)  2 (100%) NT  
Gentamicin  11 (57.8%) 1 (25%)  2(33.33%)  3 (50%) 1 (50%) NT  2(HLG) 
(100%) 
Amikacin 15 (78.9%) 3 (75%)  4(66.66%) 4 (66.6%) 1 (50%) 2  
(100%) 
2 (100%) 
Ciprofloxacin 12(63.15%)  2 (50%)  3(50%) 4 (66.6%) 1 (50%)  1 (50%) 1 (50%) 
Ofloxacin 16 (84.20%) 3 (75%)  4(66.66%) 5 (83.3%) 1 (50%)  2 (100%) 1 (50%) 
Vancomycin NT NT NT NT NT NT 2 (100%) 
 
 
 
 As per Table no.13, In CAP, Staphylococcus aureus showed  84.20% 
sensitive to Cefoxitin, Cefotaxime and Ofloxacin, least sensitive to  
Cotrimoxazole(26.30%), Amoxycillin(10.50%) and resistant to Cephalexin.  
 
 In HAP, Staphylococcus aureus showed 75% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, Amikacin, Doxycycline, least sensitive to  
Amoxycillin(25%)  and resistant to Cephalexin, . 
 
 
 In VAP, Staphylococcus aureus showed 66.66% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, Amikacin,  least sensitive to  Cotrimoxazole (16.66%), 
Amoxycillin (16.66%)   and resistant to Cephalexin. 
  
        Streptococcus pneumoniae isolated in CAP showed 100% sensitive to 
Penicillin G, Cefotaxime, Doxycycline and resistant to Cephalexin, Amoxycillin.  
 
            Enterococcus faecalis isolated in HAP showed 100% sensitive to 
Vancomycin, High level gentamicin, Doxycycline, Amikacin and resistant to 
Amoxycillin and Cotrimoxazole. 
  
 
 
TABLE NO: 14 -A– ANTIBIOTIC SENSITIVITY OF GRAM NEGATIVE 
ISOLATES FROM BLOOD SAMPLES OF PNEUMONIA PATIENTS. 
Antibiotics Klebsiella pneumoniae  Pseudomonas aeruginosa 
CAP HAP VAP CAP VAP 
(n=4) (n=1) (n=3) (n=1) (n=1) 
Amoxycillin 1 (25%) 0 0 NT  NT  
Amoxycillin -
clavulinic acid 
3 (75%) 1(100%) 1(33.33%) 0 0 
Cotrimoxazole 1 (25%) 0 0 NT  NT  
Cefoxitin 4 
(100%) 
1(100%) 3(100%) NT NT 
Cephalexin 0 0 0 NT  NT  
Cefotaxime 3 (75%) 1(100%) 2(66.66%) NT  NT  
Ceftazidime 4 
(100%) 
1(100%) 3(100%) 1(100%) 1(100%) 
Ceftriaxone 4 
(100%) 
1(100%) 3(100%) 1(100%) 1(100%) 
Gentamicin 1 (25%) 0 1(33.33%) 0 0 
Amikacin 2 (50%) 1(100%) 2(66.66%) 0 1(100%) 
Ciprofloxacin 1 (25%) 0 1(33.33%) 0 0 
Ofloxacin 2 (50%) 1(100%) 2(66.66%) 1(100%) 1(100%) 
Piperacillin –
Tazobactam 
3 (75%) 1(100%) 2(66.66%) 1(100%) 1(100%) 
Imipenem 3 (75%) 1(100%) 2(66.66%) 1(100%) 1(100%) 
Meropenem 4(100%) 1(100%) 3(100%) 1(100%) 1(100%) 
 
 As per Table no.14-A, In CAP Klebsiella pneumoniae  showed  100% 
sensitive to Meropenem ,Ceftazidime, Ceftriaxone, Cefoxitin, 25%  sensitive to 
Amoxycillin , Cotrimoxazole,  Gentamicin, Ciprofloxacin and resistant to 
Cephalexin . 
  
 In HAP, Klebsiella pneumoniae showed 100% sensitive to Piperacillin –
Tazobactam, Imipenem, Meropenem, 3rd generation Cephalosporins (Cefotaxime, 
 
 
Ceftazidime), Ofloxacin, Amikacin, cefoxitin and resistant to Amoxycillin, 
Cotrimoxazole, Gentamicin, Ciprofloxacin, Cephalexin. 
 In VAP, Klebsiella pneumoniae showed 100% sensitive to Meropenem, 
Ceftazidime, Ceftriaxone, Cefoxitin and resistant to Amoxycillin and 
Cotrimoxazole, Cephalexin.  
 Pseudomonas aeruginosa isolated in CAP and VAP showed  100% sensitive 
to Piperacillin –Tazobactam, Imipenem, Meropenem, Ceftazidime, Ceftriaxone , 
Ofloxacin, Amikacin and resistant to Gentamicin, Ciprofloxacin. 
 
TABLE NO: 14 -B– ANTIBIOTIC SENSITIVITY OF GRAM POSITIVE 
ISOLATES FROM BLOOD SAMPLES OF PNEUMONIA PATIENTS. 
Antibiotics 
Staphylococcus aureus  Coagulase Negative Staphylococcus aureus 
CAP(n=2) HAP(n=1) VAP(n=1) CAP(n=1) 
Amoxycillin 0 0 0 0  
Erythromycin 1 (50%) 0 0 0 
Doxycycline 2 (100%) 1 (100%) 0 1 (100%) 
Co-trimaxazole 1 (50%) 0 0 0 
Cefoxitin 2 (100%) 1 (100%) 1 (100%) 1 (100%) 
Cephalexin 0 0 0 0 
Cefotaxime 2 (100%) 1 (100%) 1 (100%) 1 (100%) 
Gentamicin 1 (50%) 0 0 0 
Amikacin 1 (50%) 1 (100%) 1 (100%) 1 (100%) 
Ciprofloxacin 1 (50%) 0 0 0 
Ofloxacin 2 (100%) 1 (100%) 1 (100%) 1 (100%) 
 
 As per Table no.14-B, In CAP, Staphylococcus aureus showed 100% 
sensitive to Cefoxitin, Cefotaxime and Ofloxacin, Doxycycline and resistant to 
Cephalexin, Amoxycillin. 
 
 
 In HAP, Staphylococcus aureus showed 100% sensitive to Cefoxitin, 
Cefotaxime, Ofloxacin, Amikacin, Doxycycline, and resistant to Cephalexin, 
Amoxycillin, Cotrimoxazole, Erythromycin, Gentamicin, Ciprofloxacin. 
 
 In VAP, Staphylococcus aureus showed 100% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, Amikacin, and resistant to Cephalexin, Amoxycillin and 
Cotrimoxazole and resistant to Cephalexin, Amoxycillin, Cotrimoxazole, 
Gentamicin, Ciprofloxacin. 
 
TABLE NO: 15– CHARACTERISATION OF ESBL PRODUCING          
KLEBSIELLA PNEUMONIAE 
 
PNEUMONIA 
PHENOTYPIC METHOD GENOTYPIC METHOD 
SCREENING 
POSITIVE 
PHENOTYPIC 
CONFIRMATORY 
CTX-M TEM SHV 
CAP(n=42) 13(30.95%) 11(26.19%) 11 9 10 
HAP (n=12) 6(50%) 4(33.33%) 4 2 4 
VAP (n=6) 3(50%) 3(50%) 3 2 3 
TOTAL 22 18 18 13 17 
 
  
 As per Table no.15, Distribution of  ESBL producing Klebsiella pneumoniae  
in CAP 11 (26.19%) , HAP 4 (33.33%) and VAP 3(50%) which is confirmed by 
phenotypic and genotypic  methods. 
  
 
 
TABLE NO 16–MINIMUM INHIBITORY CONCENTRATION OF 
ISOLATES OF ESBL KLEBSIELLA PNEUMONIAE TO CEFTAZIDIME 
AND CEFTAZIDIME CLAVULINIC ACID (μg/ml)    (n=18) 
           Phenotypic Confirmation of ESBL by E – Strip test 
Name of the 
Organism 
No. Of 
Strains 
Ceftazidime 
MIC 
Ceftazidime + 
Clavulanic Acid 
MIC 
Result 
K.pneumoniae 12 >32 0.25 Positive 
6 6 0.125 Positive 
 
As per table no: 16, 18 isolates of ESBL producing Klebsiella pneumoniae 
tested for MIC by E-test.  MIC value for 12 isolates is >32µg/ml for ceftazidime 
and 0.25 µg/ml for ceftazidime-clavulanic acid. MIC value for 6 isolates is 6 µg /ml 
for ceftazidime and 0.125 µg/ml for ceftazidime-clavulanic acid. As per CLSI 
guidelines 2015, MIC value of ceftazidime – clavulanate should be ≥ 8 fold 
decrease in concentration than MIC value of ceftazidime alone.  
TABLE NO: 17-DETECTION OF MBL PRODUCING PSEUDOMONAS 
AERUGINOSA IN PNEUMONIA 
 
  
 
As per Table no.17, Detection of MBL Producing Pseudomonas aeruginosa in 
1(8.3%) CAP and in VAP 2 (40%). 
PNUEMONIA MBL DETECTION 
CAP(n=12) 1(8.3%) 
HAP(n=3) 0 
VAP(n=5) 2 (40%) 
 
 
 TABLE NO: 18 – CHARACTERISATION OF Amp-C PRODUCING 
ENTEROBACTERIACEA IN PNEUMONIA 
PNEUMONIA 
KLEBSIELLA PNEUMONIAE ESCHERICHIA COLI 
No. SCREENING POSITIVE CONFIRMATORY No. 
SCREENING 
POSITIVE CONFIRMATORY 
CAP 42 1 (2.3%) 1 (2.3%) 10 0 0 
HAP 12 2(16.66%) 2(16.66%) 5 1(20%) 1(20%) 
VAP 6 1(16.66%) 1(16.66%) 4 1(25%) 1(25%) 
 
As per Table no.18, Distribution of Amp-C producing Enterobacteriacea in 
pneumonia showing resistance to Cefoxitin 30µg (<18mm) as follows: CAP 
showed 1 (2.3%) were detected as Amp-C producing Klebsiella pneumoniae. HAP 
showed 2 (16.66%) were detected as Amp-C producing Klebsiella pneumoniae and 
1 (20%) were detected as Amp-C producing Escherichia coli. VAP showed 1 
(16.66%) were detected as Amp-C producing Klebsiella pneumoniae and 1 (25%) 
were detected as Amp-C producing Escherichia coli. 
  
 
 
TABLE NO: 19 – CHARACTERISATION OF MRSA 
PNEUMONIA 
PHENOTYPIC METHOD GENOTYPIC METHOD 
SCREENING 
POSITIVE 
Vancomycin MIC E-TEST 
mec-A 
≤2µg/ml 4-8 µg/ml ≥16µg/ml 
CAP(n=19) 3 (15.78%) 3 - - 3 (15.78%) 
HAP(n=4) 1 (25%) 1 - - 1 (25%) 
VAP(n=6)  2(33.33%) 2 - - 2(33.33%) 
TOTAL 6 6 - - 6 
           
 As per Table no.19, Distribution of MRSA in CAP 3 (15.78%), HAP 1(25%) 
and 2 (33.33%) which is confirmed by Phenotypic method - Cefoxitin disc 
diffusion test (cefoxitin zone size ≤ 21mm) and mec A gene was positive for all the 
isolates of MRSA by genotype methods. All isolates of MRSA showed MIC value 
to Vancomycin <2µg/ml, so it rules out Vancomycin Resistant Staphylococcus 
aureus (VRSA).  
TABLE NO -20:  OUTCOME OF THE STUDY (n=205)  
OUTCOME CAP(n=150) HAP(n=30) VAP(n=25) 
RECOVERED  95(63.33%)  18(60%)  13(52%) 
EXPIRED  15(10%)  7(23.33%)  12(48%) 
LOST FOLLOW 
UP  40(26.66%)  5(16.66%)  0   
 As per Table no.20, Outcome of the study in pneumonia patients were 
among 40(26.66%) lost follow up, 95 (63.33%) recovered, 15(10%) expired in 
CAP. In HAP 5(16.66%) lost follow up, 18(60%) recovered and 7(23.33%) 
expired. In VAP 13(52%) recovered, 12(48%) expired. 
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DISCUSSION 
 Pneumonia remains a significant medical problem in both community as 
well as in hospital. Despite the advent of antibiotics, improved diagnostic, 
microbial techniques and sophisticated respiratory support system effective 
treatment of pneumonia still poses a huge challenge. This study aims at detecting 
the common bacterial isolates causing Pneumonia in adults with  their antibiotic  
susceptibility pattern, Methicillin Resistant Staphylococcus aureus (MRSA) and 
Extended spectrum beta lactamase (ESBL) producers in patients attending 
Government Kilpauk Medical College and Hospital  with clinical symptoms and 
radiological evidence of pneumonia. The observations were recorded, analysed and 
discussed as follows. 
 
As per Table no.1, Patients with age group of 40- 60 years were highly affected by 
Community acquired pneumonia (CAP) and Ventilator associated pneumonia 
(VAP). CAP was 70 (46.66%) which is similar to study done by   Vishak K 
Acharya et al 3(41%). VAP was 14(56%) which is in contrast to study of Saroj 
Golia et al718 (39.13%). Whereas in Hospital acquired pneumonia (HAP) more 
number of cases was detected in age group above 60 years 13(43.33%). 
As per Table no.2, Adult males were commonly  affected by pneumonia , which in 
CAP was 68% which is similar to study done by Sandeep Kumar Jain et al28 
(67.50%) and in contrast to  Vishak K Acharya et al 3 (38%) . 
 In HAP, 20 (66.66%) of males were affected which is similar to the study of 
Noyal Mariya Joseph et al 37 (57.90%). 
 
 
 In VAP, 16 (64%) of males were affected which coincides with the study of 
Neelima Ranjan  Uma et al91 65%, Masoumeh bagheri- Neasmi et al9 68.20%, 
Kotgire Santhosh A et al.13 61.53%. This is because smoking being the most 
common risk factor, men are commonly affected. 
As per Table no.3, Smoking is the common risk factor in CAP 48.66% which 
coincides with Sandeep Kumar Jain et al28  40.80%  and is in contrast to the study of 
A.V,Sowmya et al4 in which diabetes is the common risk factor with 48% . COPD 
and diabetes were the common risk factor in study by   Vishak K Acharya et al 3 
10.50%. This is because tobacco smoking may lead to impairment of mucociliary 
function thereby allowing the pathogens to survive85. Type 2 Diabetes mellitus is 
also one of the important risk factor in CAP followed by COPD and alcoholism. 
As per Table no.4, Cough is the most common presenting symptom in 94.66% of 
CAP which coincides with Sandeep Kumar Jain et al28  92.50%, other symptoms 
being  fever, breathlessness  and  chestpain.  
 In HAP 86.66% had cough as the presenting symptom. 
 VAP is based on clinical criteria (Modified CPIS- Modified Clinical 
Pulmonary Infection Score >6)8. 
As per Table no. 5, Right lower lobe was the commonly involved lung lobe seen in 
Chest radiography of pneumonia patients with 36% in CAP coinciding with 
Sandeep Kumar Jain et al28 48.30%.  
 
 
 
In HAP 33.33% had Right lower lobe involvement. 
In VAP 36% showed Right lower lobe involvement. 
As per Table no.6: Respiratory samples (Sputum & ETA) collected from 
pneumonia patients showed growth in culture as follows: 
  In CAP 83(55.33%) showed growth in sputum culture which was similar to 
the study of Sushma Sawaraj et al92 62% and in contrast to Vishak K Acharya et al 3 
39%, Sandeep Kumar Jain et al28 36.70%. 
 In HAP 26(86.66%) showed growth in sputum culture.  
 In VAP 25(100%) showed growth in Endotracheal aspirate culture 
coinciding with study of Saroj Golia et al752 (100%). 
 Bacteremia being one of the complications of Pneumonia, it’s important to 
do blood culture in pneumonia patients with fever (temp>37.8ºC). In CAP 8(10%) 
showed growth in Blood culture which coincides with Sandeep Kumar Jain et al28 
9.2%, A.V. Sowmya et al4   9.33%. 
As per Table no.7- Direct gram stain of respiratory samples is used to determine 
whether a sample is representative of the site of infection or contamination as per 
Barlett’s grading48,50. Respiratory samples with direct smear positive showing 
culture positive were 80(53.33%) of CAP, 24(80%) of HAP and 21(84%) of 
VAP.This is similar to the study done by Mariaraj et al.93 (63.20%), Anuradha 
Mokkapati et al 94 (89.74%) . 3(2%) samples of CAP, 2(6.66%) of HAP and 4(16%)  
of VAP showed direct smear negative  but culture positive indicating that culture is 
 
 
the gold standard. So Gram staining can be used as preliminary screening 
technique. 
As per Table no.8, Culture growth from respiratory samples of pneumonia patients 
showed results as follows:  
 In CAP, 71(85.54%) showed monomicrobial growth and 12(14.45%) 
showed Polymicrobial growth.  
 In HAP, 20(76.92%) showed monomicrobial growth in culture and 
6(23.07%) showed polymicrobial growth which was in contrast to Vasuki et 
al18 were 8.3% showed polymicrobial growth.  
 In VAP, 24(96%) showed monomicrobial growth and 1(4%) showed 
polymicrobial growth . Similar observation was seen in the study of S 
Qureshi et al 8 were 94.74% was monomicrobial and 5.26% was 
polymicrobial. This is  in contrast to study of Saroj Golia et al7 were 86.54% 
was monomicrobial ,13.46% polymicrobial and Kotgire Santhosh A et al.13 
were 43% was monomicrobial and 56% polymicrobial . 
As per Table no. 9, Among the organisms isolated from respiratory samples of 
pneumonia patients , Gram negative bacilli was the predominant isolate in 
68(71.57%) samples of  CAP, 24(75%)  of HAP. In VAP 20(76.92%) were Gram 
negative bacilli which is similar to the study of Neelima Ranjan Uma et al91 
95.70%. Gram positive cocci accounts for about 27(28.42%) in CAP, 8(25%) in 
HAP, 6 (23.07%) in VAP. 
 
 
Gram negative bacilli was also the predominant isolate in blood culture of CAP 
(62.50%) and VAP (80%). Gram positive cocci was about 3(37.50%) in CAP, 
1(50%) in HAP and 1(20%) in VAP. 
  
As per Table no.10, Klebsiella pneumoniae was the predominant organism grown 
in respiratory samples: 
 In CAP, 42 (44.21%) were isolated which coincides with the study of  
A.V,Sowmya et al4  34.62%    and was in contrast to  Sandeep Kumar Jain et 
al28, and Vishak K Acharya et al 3 where Streptococcus pneumoniae was the 
predominant organism followed by Klebsiella pneumoniae . 
  In HAP, 12 (37.50%) were Klebsiella pneumonia, which coincides with 
study of Vasuki et al18 48.20%. 
  In VAP, both Klebsiella pneumoniae and Staphylococcus aureus  were 
isolated in 6(23.07%) samples which coincides  with the study of  Kotgire 
Santhosh A et al.13  with 16.21% and 20.27% respectively  . 
 Among Gram positive cocci, Staphylococcus aureus isolated in 19(20%) 
samples of CAP, 4(12.50%) of HAP and 6(23.07%) of VAP. 
 Among non-fermenters, Pseudomonas aeruginosa was isolated in 
12(12.63%) samples of CAP, 3(9.37%) of HAP and 5(19.23%) of VAP. 
As per Table no.11, Klebsiella pneumoniae was the predominant organism isolated 
in blood culture of 4 (50%) samples of CAP which was similar to the study of 
A.V.Sowmya et al4 50% and also from 3(60%) samples of VAP. 
 
 
As per Table no.12-A, Antibiotic sensitivity pattern of Gram negative isolates in 
CAP were as follows: 
 Klebsiella pneumoniae showed 100% sensitive to  Meropenem ,  97.61% 
sensitive to Piperacillin –Tazobactam and Imipenem , 66.66 % sensitive to  
3rd generation Cephalosporins (Cefotaxime , Ceftazidime) and 
Amikacin(61.90%) with least sensitive for Cotrimoxazole (11.90%) and 
Amoxycillin(11.90%). while study done by  Sushma Sawaraj et al92 showed 
100% sensitivity to Imipenem. 
 Pseudomonas aeruginosa was  100% sensitive to  Piperacillin –Tazobactam 
and Cefoxitin, 91% sensitive to Imipenem, Meropenem  and 3rd generation 
Cephalosporins (Ceftazidime, Ceftriaxone) with least sensitive to 
Gentamicin (50%), while study done by by  Sushma Sawaraj et al 92 showed 
90% sensitivity to 3rd generation Cephalosporins  and 50% sensitivity to 
Imipenem .  
 Escherichia coli was 100% sensitive to  Piperacillin –Tazobactam, 
Imipenem, Meropenem, 3rdgeneration Cephalosporins (Cefotaxime,  
Ceftazidime) and Cefoxitin, 80% sensitive to Amikacin, 60% sensitive to 
Ofloxacin, 50%sensitive to Amoxyclavulanic acid, Gentamicin and 
ciprofloxacin , 30% sensitive to Cotrimoxazole and Cephalexin, whereas in 
study done by by  Sushma Sawaraj et al92 it showed 81.80% sensitivity to 
Imipenem .  
As per Table no.12-B, Antibiotic sensitivity pattern of Gram negative isolates in 
HAP were as follows:  
 
 
  Klebsiella pneumoniae  showed 100% sensitive to Imipenem, Meropenem, 
91% sensitive to Piperacillin/Tazobactam, 83.30% sensitive to cefoxitin, 
50% sensitive to  3rd generation Cephalosporins (Cefotaxime, Ceftazidime)  
and Amikacin with least sensitive for Cotrimoxazole(16.66%), 
Amoxycillin(8.3%) and cephalexin(0). In the study done by Vasuki et al 18, 
Klebsiella pneumoniae showed 100% sensitivity to Imipenem.  
 Escherichia coli showed 100% sensitivity to Piperacillin –Tazobactam, 
Imipenem, Meropenem and 3rd generation Cephalosporins (Cefotaxime, 
Ceftazidime), resistant to Amoxycillin and cephalexin. In the study done by 
Vasuki et al 18 , Escherichia coli showed 100% sensitivity to Imipenem  . 
 Pseudomonas aeruginosa was 100% sensitive to Piperacillin –Tazobactam, 
Meropenem and Ceftriaxone, and was least sensitive to ciprofloxacin 
(33.30%) and Gentamicin (33.30%). In the study done by Vasuki et al18, 
Pseudomonas aeruginosa showed 100% sensitivity to Imipenem. 
As per Table no.12-C, Antibiotic sensitivity pattern of Gram negative isolates in 
VAP as follows: 
 Klebsiella pneumoniae  showed  100% sensitive to Meropenem, 83.30% 
sensitive to Piperacillin –Tazobactam, Imipenem, Cefoxitin, 50% sensitive 
to 3rd generation Cephalosporins (Cefotaxime, Ceftazidime), Ofloxacin,  
Amikacin, with least sensitive to  Gentamicin(16.66%), 
Amoxycillin(16.66%), Cotrimoxazole(0) and Cephalexin(0).whereas study 
done by Saroj Golia et al7, 100%  sensitive to Piperacillin –Tazobactam, 
 
 
Meropenem, Imipenem.  S Qureshi et al8 100% sensitive to Meropenem and 
Imipenem, 77% sensitive to Piperacillin –Tazobactam. 
 Pseudomonas aeruginosa showed 80% sensitive to Piperacillin Tazobactam, 
60% sensitive to Imipenem, Meropenem, 3rd generation Cephalosporins 
(Ceftazidime, Ceftriaxone), Ofloxacin, Amikacin, with least sensitive to 
ciprofloxacin(20%) in this study whereas study done by Saroj Golia et al7, 
Pseudomonas aeruginosa showed  45% sensitive to Piperacillin-
Tazobactam, Ceftazidime, 60% sensitive to Meropenem, Imipenem. S 
Qureshi et al 8 77% sensitive to Meropenem, Imipenem and Piperacillin-
Tazobactam, 44% sensitive to 3rd generation Cephalosporins (Ceftazidime). 
 Acinetobacter baumanii  showed 100% sensitive to Meropenem, 3rd 
generation Cephalosporins(Ceftazidime, Ceftriaxone), 80% sensitive to 
Piperacillin –Tazobactam, Imipenem,  with least sensitive ciprofloxacin 
(20%) in this study, whereas study done by Saroj Golia et al7, Acinetobacter 
baumanii  showed 62.50% sensitive to Meropenem, Imipenem, 25%  
sensitive to Piperacillin –Tazobactam, S Qureshi et al8  showed 100% 
sensitive to Piperacillin –Tazobactam, Meropenem, Imipenem. 
 Escherichia coli  showed 100%  sensitive to Piperacillin –Tazobactam , 
Meropenem,75% sensitive to Imipenem, 3rd generation Cephalosporins 
(Cefotaxime,Ceftazidime), Cefoxitin, 50% sensitive to Amikacin and 
Ofloxacin, 25% sensitive to Amoxycillin-clavulanic acid, Gentamicin, 
ciprofloxacin and resistant to cotrimoxazole, cephalexin, Amoxycillin in this 
study, whereas study done by Saroj Golia et al7, Escherichia coli showed 
 
 
100%  sensitive to Piperacillin –Tazobactam, Meropenem, Imipenem, S 
Qureshi et al 8  100%  sensitive to Meropenem, Imipenem ,77% sensitive to 
Piperacillin –Tazobactam. 
As per Table no.13, Gram positive organism isolated from respiratory samples of 
pneumonia patients as follows: 
 In CAP, Staphylococcus aureus showed 84.20% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, least sensitive to  Cotrimoxazole(26.30%), 
Amoxycillin(10.50%) and resistant to Cephalexin. whereas study done by  
Sushma Sawaraj et al92 showed  82.30% sensitive to Cefoxitin. 
 In HAP, Staphylococcus aureus showed 75% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, Amikacin, Doxycycline, least sensitive to  
Amoxycillin(25%)  and resistant to Cephalexin. whereas study done by 
Vasuki et al 18, Staphylococcus aureus showed  93.54%  sensitive to 
Cefotaxime. 
 In VAP, Staphylococcus aureus showed 66.66% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, Amikacin, least sensitive to  Cotrimoxazole 
(16.66%) , Amoxycillin (16.66%)   and resistant to Cephalexin, whereas 
study done by Saroj Golia et al7, Staphylococcus aureus  showed 28.57% 
sensitive to  Erythromycin, 14.29%  sensitive to Cefoxitin. Study done by S 
Qureshi et al8 showed 50% sensitive to Cefoxitin, Erythromycin, 
Doxycycline,  Gentamicin  and resistant to  Cotrimoxazole. 
 Streptococcus pneumoniae isolated in CAP showed 100% sensitive to 
Penicillin G, Cefotaxime, Doxycycline and resistant to Cephalexin, 
 
 
Amoxycillin. whereas study done by  Sushma Sawaraj et al92 showed 56% 
sensitive to Cefotaxime, 18.7% sensitive to Penicillin G. 
 Enteroccus  faecalis showed 100% sensitive to Vancomycin, High level 
gentamicin, Doxycycline, Amikacin and resistant to Amoxycillin and 
Cotrimoxazole. 
 
As per Table no.14-A, Gram negative organism isolated from blood samples of 
pneumonia patients as follows: 
            In CAP Klebsiella pneumoniae showed 100% sensitive to Meropenem, 
Ceftazidime, Ceftriaxone, Cefoxitin, 25% sensitive to Amoxycillin, Cotrimoxazole, 
Gentamicin, Ciprofloxacin and resistant to Cephalexin. 
 In HAP, Klebsiella pneumoniae showed 100% sensitive to Piperacillin –
Tazobactam, Imipenem, Meropenem, 3rd generation Cephalosporins (Cefotaxime, 
Ceftazidime), Ofloxacin, Amikacin, cefoxitin and resistant to Amoxycillin, 
Cotrimoxazole, Gentamicin, Ciprofloxacin, Cephalexin. 
 In VAP Klebsiella pneumoniae showed 100% sensitive to Meropenem, 
Imipenem, Ceftazidime, Ceftriaxone, Cefoxitin and resistant to Amoxycillin and 
Cotrimoxazole, Cephalexin.  
 Pseudomonas aeruginosa isolated in CAP and VAP showed  100% sensitive 
to Piperacillin –Tazobactam, Imipenem, Meropenem, Ceftazidime, Ceftriaxone, 
Ofloxacin, Amikacin and resistant to Gentamicin, Ciprofloxacin. 
 
 
 
As per Table no.14-B, Gram positive organism isolated from blood samples of 
pneumonia patients as follows: 
 In CAP, Staphylococcus aureus showed 100% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, Doxycycline and resistant to Cephalexin, 
Amoxycillin. 
 
 In HAP, Staphylococcus aureus showed 100% sensitive to Cefoxitin, 
Cefotaxime, Ofloxacin, Amikacin, Doxycycline, and resistant to 
Cephalexin, Amoxycillin, Cotrimoxazole, Erythromycin, Gentamicin, 
Ciprofloxacin. 
 In VAP, Staphylococcus aureus showed 100% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, Amikacin, and resistant to Cephalexin, 
Amoxycillin and Cotrimoxazole and resistant to Cephalexin, Amoxycillin, 
Cotrimoxazole, Gentamicin, Ciprofloxacin. 
As per Table no.15, Extended spectrum betalactamases has lead to ineffectiveness 
of antibiotics and increase in the severity of illness due to various pathogenic strain 
causing pneumonia11. Screening of ESBL was done by disk diffusion method 
(30.95% in CAP, 50% in HAP & 50% in VAP) and it is confirmed by phenotypic 
confirmatory disk diffusion method.  
 In CAP, 11(26.19%) was ESBL K.pneumoniae with CTX-M is common 
gene obtained in this study which coincides with the study of                   
Arijit Bora et al90. 
 In HAP, 4(33.33%) which is contrast to the study of Vasuki et al18 82%. 
 
 
 
 InVAP, 3 (50%) which is contrast to the study of S Qureshi et al 8 75%, 
Kotgire Santhosh A et al.13 33.33%, Veena Krishna Murthy et al11 
32.10%.Genotypic study of ESBL K.pneumoniae isolates in VAP coincides 
with the study of Veena Krishna Murthy et al11.CTX-M is the predominant 
gene isolated followed by TEM and SHV gene in Genotypic study of ESBL 
K.pneumoniae. 
As per table no: 16, 18 isolates of ESBL producing Klebsiella pneumoniae tested 
for MIC by E-test. MIC value for 12 isolates is >32µg/ml for ceftazidime and 0.25 
µg/ml for ceftazidime-clavulanic acid. MIC value for 6 isolates is 6 µg /ml for 
ceftazidime and 0.125 µg/ml for ceftazidime-clavulanic acid. As per CLSI 
guidelines 2015, MIC value of ceftazidime – clavulanate should be ≥ 8 fold 
decrease in concentration than MIC value of ceftazidime alone. 
As per Table no.17, Meropenem: 10μg (MRP) (Zone of inhibition ≤ 18mm) 
resistant Pseudomonas aeruginosa isolates was taken for screening MBL 
production.   Antibiotic sensitivity testing was done by the Kirby-Bauer disc 
diffusion method. 
MBL Producing Pseudomonas aeruginosa was detected by isolates showing 
resistance to Meropenem 10μg (Zone of inhibition ≤18mm) as follows: 1(8.3%) 
CAP. 2 (40%) in VAP as MBL Producing Pseudomonas aeruginosa which 
coincide with the study of Saroj Golia et al7 40%, S Qureshi et al 8 37.50% and 
contrast to the study Kotgire Santhosh A et al.13 1.5% 
 
 
 
As per Table no.18, Distribution of Amp-C producing Enterobacteriacea in 
pneumonia showing resistance to Cefoxitin (<18mm) as follows: 
 CAP showed 1 (2.3%) were detected as Amp-C producing Klebsiella 
pneumonia.  
 HAP showed 2(16.66%) were detected as Amp-C producing Klebsiella 
pneumoniae and 1 (20%) were detected as Amp-C producing Escherichia 
coli. 
 VAP  showed 1(16.66%) were detected as Amp-C producing Klebsiella 
pneumoniae which is in contrast to the study of Kotgire Santhosh A et al.13 
33.33%. 1(25%) were detected as Amp-C producing Escherichia coli in 
VAP which coincides with the study of  Noyal Mariya Joseph et al95 25%. 
As per Table no.19, Early detection and treatment of MRSA is very important to 
prevent complications and fatal outcomes. Distribution of MRSA in Pneumonia 
patients as follows: 3(15.78%) in CAP which coincides with the study of Sushma 
Sawaraj et al92 17.64%. 
 1(25%) MRSA in HAP which is in contrast to the study of Vasuki et al18 
6.20% and Chiranjoy Mukhopadhyay et al 34 53.30%. 
 2(33.33%) in VAP were MRSA in this study whereas MRSA in other studies 
as follows: Kotgire Santhosh A et al.13 53.33%, S Qureshi et al 8 66.70% and Saroj 
Golia et al7 85.71%. All isolates of MRSA showed MIC value to Vancomycin 
<2µg/ml, so it rules out Vancomycin Resistant Staphylococcus aureus  (VRSA). 
 
 
As per Table no.20, Impact of various risk factors and the emergence of multidrug 
resistant pathogens determines the outcome of the disease. Outcome of the study is 
as follows:  
 In CAP, 40(26.66%) lost follow up, 95 (63.33%) recovered, 15(10%) 
expired. Mortality rate in CAP was about 50% in the study done by 
A.P.Misra et al 96 
 In HAP, 5(16.66%) lost follow up, 18(60%) recovered and 7(23.33%) 
expired. Mortality rate is contrast to the study of Hina Gadani et al97 41.20%. 
 In VAP, 13(52%) recovered, 12(48%) expired. Mortality rate in VAP 
coincide with the study of Neelima Ranjan Uma et al91 48.33%, S Qureshi et 
al8 48.57%. Mortality rate in VAP is mostly due to multidrug resistant 
pathogen. 
 As Pneumonia is one of the major causes of morbidity and mortality in 
hospital as well as in community due to varied etiopathogenesis, it is necessary to 
do culture of respiratory samples (sputum and ETA) in order to identify the 
pathogen thereby to know the antibiotic sensitivity pattern. In view of the changing 
patterns of bacterial resistance to common drugs, the administration of antibiotics 
must be judicious to prevent the emergence of bacterial resistance in the hospital 
and the community.                                                                                                           
                                                
 
 
SUMMARY 
Pneumonia is a disease known to mankind from antiquity. Respiratory 
samples (Sputum, endotracheal aspirate) and blood samples were collected from 
patients with clinically suspected and radiological evidence of pneumonia in adult 
patients, attending medicine OP and also admitted in IMCU and other wards at 
Government Kilpauk Medical College and Hospital, Chennai from January 2015 
to June 2016. 
 
Patients with age group of 40-60 years were commonly affected in CAP 
and VAP, whereas in HAP age group above 60 years were commonly affected. 
Males are commonly affected by pneumonia in this study. The culture positives 
with respiratory samples of patient with pneumonia were 83(55.33%) in CAP, 
26(86.66%) in HAP, 25(100%) in VAP. Gram negative bacilli were the 
predominant bacteria isolated with 68(71.57%) in CAP, 24(75%) in HAP, 
20(76.92%) in VAP. The culture positives with blood samples of patient with 
pneumonia were 8 (10%) in CAP, 2(16.66%) in HAP, 5(20%) in VAP.  
 
Klebsiella pneumoniae was the major isolate constituting about 42 
(44.21%) in CAP followed by Staphylococcus aureus constituting about 19 
(20%) in CAP. In HAP, 12 (37.50%) were Klebsiella pneumoniae followed by 
Escherichia coli 5 (15.62%) & Staphylococcus aureus  4(12.50%). In VAP, 
6 (23.07%) were Klebsiella pneumoniae and Staphylococcus aureus followed by 
Pseudomonas aeruginosa& Acinetobacter baumanii which was about 
12(19.23%). 
 
 
      In CAP, Klebsiella pneumoniae showed 100% sensitive to  Meropenem, 
97.61% sensitive to Piperacillin –Tazobactam and Imipenem, 66.66 % sensitive 
to  3rd generation Cephalosporins (Cefotaxime, Ceftazidime) and Amikacin 
(61.90%) with least sensitive for Cotrimoxazole (11.90%) and Amoxycillin 
(11.90%). 
 
         In HAP, Klebsiella pneumoniae  showed 100% sensitive to Imipenem, 
Meropenem, 91% sensitive to Piperacillin/Tazobactam, 83.30% sensitive to 
cefoxitin, 50% sensitive to  3rd generation Cephalosporins (Cefotaxime, 
Ceftazidime) with least sensitive for Cotrimoxazole (16.6%), cephalexin (0) and 
Amoxycillin (8.30%).   
 
             In VAP, Klebsiella pneumoniae  showed  100% sensitive to Meropenem, 
83.30% sensitive to cefoxitin, Piperacillin –Tazobactam, Imipenem, 50% 
sensitive to 3rd generation Cephalosporins (Cefotaxime, Ceftazidime) with least 
sensitive to  Gentamicin (16.60%) and Amoxycillin (16.60%). 
 
            In CAP, Staphylococcus aureus showed  84.20% sensitive to Cefoxitin, 
Cefotaxime and Ofloxacin, least sensitive to Cotrimoxazole (26.30%), 
Amoxycillin (10.50%) and resistant to Cephalexin.  
 
 In HAP, Staphylococcus aureus showed 75% sensitive to Cefoxitin, 
Cefotaxime, Ofloxacin, Amikacin, Doxycycline, least sensitive to Amoxycillin 
(25%) and resistant to Cephalexin. 
 
 
 
 In VAP, Staphylococcus aureus showed   66.66% sensitive to Cefoxitin, 
Cefotaxime, Ofloxacin, Amikacin, least sensitive to  Cotrimoxazole (16.66%),  
Amoxycillin (16.66%)   and resistant to Cephalexin. 
 
   Among the Klebsiella pneumoniae, distribution of ESBL 11(26.19%) in 
CAP, 4(33.33%) in HAP, 3(50%) in VAP identified by phenotypic method &   
CTX-M is the most common gene identified by genotypic method. 
 
             Among Pseudomonas aeruginosa, MBL producers were detected by 
isolates showing resistant to Meropenem. Distribution of MBL producing 
Pseudomonas aeruginosa were 1(8.3%) in CAP, 2 (40%) in VAP. 
 
           Distribution of Amp-C producing Enterobacteriacea in pneumonia 
showing resistance to Cefoxitin (Zone size <18mm) were 1 (2.3%)  Klebsiella 
pneumoniae and 1 (20%) Escherichia coli in CAP, VAP showed 1(16.66%) were 
Klebsiella pneumoniae and 1(25%) were Escherichia coli. 
 
               Distribution of MRSA in Pneumonia patients were 3(15.78%) in CAP, 
1(25%) in HAP and 2(33.33%) in VAP. All isolates of MRSA showed MIC value 
to Vancomycin <2µg/ml, so it rules out Vancomycin Resistant Staphylococcus 
aureus  (VRSA).mec A gene was positive for all the 6 isolates of MRSA. 
 
 
 
 
 
          Outcome of the study in pneumonia patients were among 40 (26.66%) lost 
follow up, 95 (63.33%) recovered, 15(10%) expired in CAP. In HAP 5 (16.66%) 
lost follow up, 18(60%) recovered and 7(23.33%) expired. In VAP 13(52%) 
recovered, 12(48%) expired. 
 
 Early diagnosis of pneumonia and administration of specific antibiotic 
therapy, based on the antibiogram of the isolated pathogen will reduce the 
complication as well as the emergence of drug resistance, thereby hasten the 
recovery of the patients. This will lead to better outcome and effective patient 
care.  
 
                  
  
 
 
CONCLUSION 
 Pneumonia remains a common and serious disease with significant 
morbidity and mortality in developing as well as in developed nation. 
 The present study showed that Gram negative bacilli were the predominant 
bacteria isolated from Pneumonia in adult patients. 
 
 Among the Gram negative bacilli, Klebsiella pneumoniae was found to be the 
most common bacterial pathogen isolated with many ESBL producing strains 
which were 100% sensitivity to Meropenem. CTX-M was the most common 
gene identified among the ESBL isolates by molecular method. 
 
 Among Gram positive organisms, Staphylococcus aureus was the predominant 
isolate. MRSA strains were detected, which showed the presence of mec A 
gene and all the strains were sensitive to Vancomycin (MIC E-test).  
 
Early diagnosis of the disease with specific knowledge of the causative agents 
along with their isolation and sensitivity pattern will serve as an vital tool for 
reducing the morbidity and mortality of pneumonia. Strict adherence to infection 
control policy and antibiotic stewardship will reduce the emergence of drug 
resistant strains in pneumonia leading to faster recovery in better health care 
facilities. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
PROFORMA 
 
Name:                                                                    OP/IPno: 
Age/Sex:                                                                Ward: 
Occupation:                                                           Micro.lab no: 
Address:                                                                Date: 
Complaints: 
Comorbidity: 
H/o Antibiotics/ Hospitalisation(duration): 
H/o smoking / alcohol intake: 
If patient on ventilator (duration): 
Clinical examination: 
Vital signs: PR-           RR-           Temp-   BP-                    Spo2- 
Clinical diagnosis- 
Diagnosis based on classification- 
Investigation: 
Total WBC count-                 
Chest X-ray: 
Microbiology investigation: 
Samples collected- 
1.Sputum for AFB- 
2.Culture &Sensitivity (Sputum/Endotracheal aspirate) 
Macroscopic examination- 
Microscopic examination- 
Direct Gram stain- 
Bacterial Culture- 
Organism- 
 
 
Antibiotic Sensitivity- 
ESBL/MRSA/MBL/AMP C- 
2.Blood culture &Sensitivity- 
Culture- 
Organism- 
Antibiotic Sensitivity- 
ESBL/MRSA/MBL/AMP C- 
OUTCOME- 
 
          
 
 
 
 
                                                              
 
 
 
 
 
 
சுய ஒப்புதல் படிவம் 
ஆய்வு செய்யப்படும் தலைப்பு: "CHARACTERISATION OF BACTERIAL ISOLATES WITH 
DETECTION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AND EXTENDED SPECTRUM 
BETALACTAMASE PRODUCERS IN ADULT PNEUMONIA" . 
ஆய்வு செய்யப்படும் இடம்: கீழ்பாக்கம் அரசு மருத்துவக்கல்லூரி மற்றும்                                            
மருத்துவமனை, சென்னை-10 
பங்கு சபறுபவரின் சபயர்:  
பங்கு சபறுபவரின் வயது:                                           பங்குசபறுபவரின் எண் : 
 மமமே குறிப்பிட்டுள்ள மருத்துவ ஆய்வின் விவரங்கள் எைக்கு 
விளக்கபட்டுள்ளது. நான் இவ்வாய்வில் தன்ைிச்னெயாக பங்மகற்கின்மறன். எந்த 
காரணத்திைாமோ, எந்த ெட்ட ெிக்கலுக்கும் உட்படாமல் நான் இவ்வாய்வில் இருந்து 
விேகிக் சகாள்ளோம் என்றும் அறிந்துசகாண்மடன். 
  இந்த ஆய்வு ெம்பந்தமாகமவா, இனத ொர்ந்து மமலும் ஆய்வு மமற்சகாள்ளும் 
மபாதும் இந்த ஆய்வில் பங்குசபறும் மருத்துவர் என்னுனடய மருத்துவர் 
என்னுனடய மருத்துவ அறிக்னககனள பார்ப்பதற்கு என் அனுமதி மதனவ இல்னே 
எை அறிந்து சகாள்கிமறன். இந்த ஆய்வின் மூேம் கினடக்கும் 
தகவனேமயா,முடினவமயா பயன்படுத்திக் சகாள்ள மறுக்கமாட்மடன். 
         இந்த ஆய்வில் பங்கு சகாள்ள ஒப்புக் சகாள்கிமறன். இந்த ஆய்னவ 
மமற்சகாள்ளும் மருத்துவ அணிக்கு உண்னமயுடன் இருப்மபன் என்று 
உறுதியளிக்கிமறன். 
பங்மகற்பவரின் னகசயாப்பம்:                                         ொட்ெியாளரின் 
னகசயாப்பம் 
இடம்:                                                                                     இடம்: 
மததி:                                                                                        மததி : 
பங்மகற்பவரின் சபயர் மற்றும் விோெம்: 
ஆய்வாளரின்  னகசயாப்பம்: 
இடம்:                                    மததி:             
 
 
PATIENT CONSENT FORM 
 
STUDY DETAIL: “CHARACTERISATION OF BACTERIAL ISOLATES WITH 
DETECTION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 
AND EXTENDED SPECTRUM BETALACTAMASE PRODUCERS IN ADULT 
PNEUMONIA’’. 
 
STUDY CENTER: 
KILPAUK MEDICAL COLLEGE AND HOSPITAL, CHENNAI. 
PATIENT NAME:     PATIENT AGE: 
IDENTIFICATION NUMBER: 
PATIENT TO TICK   THESE BOXES  
 
I conform that I have understood the purpose of procedure for the above study.  
 
I have the opportunity to ask the question and all my questions and doubts have been 
answered to my satisfaction. 
 
I understand that my participation in the study is voluntary and that I am free to withdraw 
at anytime without giving any reasons, without my legal rights being affected. 
 
I understand that investigator, regulatory authorities and the ethics committee will not need 
my permission to look at my health records both in respect to the current study and any 
further research that may be conducted in relation to it, even if withdraw from the study, I 
understand that my identity will not be revealed in any information released to third parties 
or published, unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
 
I agree to take part in the above study and to comply with the instructions given during the 
study and faithfully cooperative with the study team and to immediately inform the study 
staff if I suffer from any deterioration in my health or wellbeing or any unexpected or 
unusual symptoms. 
 
I hereby give consent to participate in this study. 
 
I hereby give permission to undergo complete clinical examination and diagnostic test. 
Signature/Thumb impression:    Place:   Date: 
Patient name and address: 
 
Signature of the investigator:     Place:   Date: 
Study investigator’s name: 
 
 
 
 
APPENDIX 
GRAM STAIN 
Primary stain  crystal violet 10g 
   Absolute alcohol 100ml 
   Distilled water 1 litre 
Mordant   Grams iodine 10g 
   Potassium iodide 20g 
   Distilled water-1litre 
Decolouriser  Acetone 
Counter stain- Dilute Carbol fuchsin 
1. Flood the crystal violet for one minute  
2. Rinse gently with distilled water 
3. Flood the slide with grams iodine for one minute 
4. Rinse gently with distilled water 
5. Decolourise with acetone for only 2-3 secs 
6.  Rinse gently with distilled water to remove excess of 
decolouriser 
7. Flood the slide with dilute carbol fuchsin for one minute 
8. Rinse the slide with distilled water air dry and examine under oil 
   immersion objective 
  
 
 
PEPTONE WATER 
Peptone                                       10g 
Sodium chloride                            5g 
Distilled water                              1 litre 
Dissolve the ingredients in warm water, adjust the pH to 7.4 - 7.5 and filter. 
Distribute as required and autoclave at 121 degree Celsius for 15 mins. 
Brain Heart Infusion broth:- 
                                     
Calf brain infusion          200g 
Beef heart infusion         250g 
Proteose peptone              10g 
Dextrose                            2g 
Sodium chloride               5g 
Disodium phosphate       2.5g 
Distilled water     1000ml 
 
Add the contents and dissolve by heating. 
Adjust the pH to 7.4 + 0.2. Autoclave at 121ºC for 15 minutes. 
 
  
 
 
MacConkey agar:- 
 This is a useful medium for the cultivation of Enterobacteriacea. It 
contains a bile salt to inhibit non-intestinal bacteria and lactose with neutral 
red to distinguish the lactose-fermenting coli forms from the lactose –non-
fermenting Salmonella and Shigella groups. The concentration of sodium 
taurocholate may be reduced to suit less tolerant organisms. The omission of 
sodium chloride from the medium prevents the spreading of Proteus colonies. 
Peptone                                                           20 g 
Sodium taurocholate     5 g 
Water                                                                1 litre 
Agar                                                              20 g 
Neutral red solution, 2% in 50% ethanol     3.5 ml 
Lactose, 10% aqueous solution        100 ml 
 
Dissolve the peptone and taurocholate (bile salt) in the water by 
heating. Add the agar and dissolve it in the steamer or autoclave. If necessary, 
clear by filtration. Adjust the pH to 7.5. Add the lactose and the neutral red, 
which should be well shaken before use, and mix. Heat in the autoclave with 
‘free steam’ (100o C) for 1hr, then at 115o C for 15 min. poured in plates. 
 
 
 
Nutrient agar:-      
Peptic digest of animal tissue                   5g 
 Beef extract                  1.5g 
Yeast extract                          5g 
Agar                                                 15g 
Distilled water     1000ml 
Dissolve the contents in water and mix by heating  Autoclave at 121o C 
for 15 minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml of 9 cm diameter. Petri 
dishes to give 4 mm thickness. 
Blood agar:- 
Sterile sheep blood                       50 ml 
Peptone                                    10 g 
Beef extract                                              3g 
Sodium chloride                            5 g 
Distilled water                         1000 ml 
Autoclave the nutrient agar base at 121o C for 15 minutes and cooled to 50o C. 
Then the blood is added with sterile precautions and distribute in Petri dishes. 
  
 
 
Chocolate agar:- 
Sterile sheep blood                 50ml 
Peptone                            10 g 
Beef extract                                      3g 
Sodium chloride                                   5 g 
Distilled water                                 1000 ml 
 Autoclave the nutrient agar base at 121o C for 15 minutes and allow the 
medium to be at 75o C. Then the blood is added with sterile precautions with 
gentle agitation from time to time and the colour of the medium is chocolate 
brown. Distribute in Petri dishes. 
Mueller Hinton agar:-   
Beef infusion     300 ml 
Casein hydrolysate    17 gm 
Starch      1.5 gm 
Agar      10 gm 
Distilled water     1000 ml 
Emulsify the starch in a small amount of cold water, pour into the beef 
infusion and add the casein- hydrolysate and the agar. Make up the volume to 
1000 ml (1 litre) with distilled water. Dissolve the constituents by heating 
gently at 100o C with agitation. 
 
 
 Adjust the pH to 7.4. Dispense in screw-capped bottles and sterilize by 
autoclaving at 121 o C for 20 minutes. 20 to 25 ml of it is poured into Petri 
dishes of 9 cm diameter to give a thickness of 4mm. 
McFarland Turbidity Standards for inoculum preparation 
A Barium sulphate 0.5 McFarland standards was prepared as follows 
1. A 0.5 ml of 0.048mol/L of Barium chloride was added to 99.5 ml of 0.18 
mol/L of H2SO4 with constant stirring to maintain a suspension.  
2. Correct density of the turbidity standard was verified by using a 
spectrophotometer. The absorbance of 625nm should be 0.08 to0.10 for 
the 0.5 McFarland standards. 
3. The Barium sulphate suspension was transferred in 4-6 ml to a screw 
capped tube of the same size as those used in growing or diluting the 
bacterial inoculum. 
4. These tubes were tightly sealed and stored in the dark at room 
temperature. 
5. The Barium sulphate turbidity standard was vigorously agitated before 
each use and inspected for a uniform turbid appearance 
 
 
 
 
 
Differentiating Characters of Isolates Commonly Observed In 
Pneumonia patients Among Gram positive cocci 
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Is
ol
at
e 
Cocci in 
cluster 
Positive Negative ± Positive Positive Negative Resis
tant 
Negative Staphylococcus 
aureus 
Cocci in 
cluster 
Positive Negative ± Negative Negative Negative Resis
tant 
Negative Coagulase 
negative 
Staphylococcus 
aureus 
Cocci in 
pairs 
Negative Negative α -
hemolysis 
Negative Negative Negative Resis
tant 
Positive Streptococcus 
pneumoniae 
Cocci in 
pairs  
Negative  Negative ± Negative ± Positive Resis
tant 
Negative Enterococci 
 
Differentiating Characters Of Isolates Commonly Observed In 
Pneumonia patients Among Gram Negative Bacilli 
Organism 
TSI 
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Klebsiella 
Pneumoniae 
A/A with 
gas Utilised - - + + + + + + - 
Escherichia 
coli 
A/A with 
gas 
Not 
utilised + - + + + - + + + 
Pseudomonas 
aeruginosa 
K/No 
change Utilised - + + - - - + - + 
Proteus sp. 
species 
K/A with 
H2S Utilised + - + + - + - - + 
Serratia 
marcesens 
K/A Utilised - - + + - + - - + 
Acinetobacte
r species 
K/No 
Change 
 Not 
utilised - - + - - - - - - 
 
 
Note:   A/A = Acid slant / Acid butt, K/A = Alkaline slant / Acid butt,  
+   = Positive,  - =   Negative    
 
ZONE SIZE INTERPRETATIVE CHART IN ACCORDING TO CLSI -
2015 Kirby-Bauer Chart 
Sl. 
No. Drug 
Disk 
Content 
µg 
Resistant 
mm or 
less 
Intermediat
e 
mm 
Sensitiv
e 
mm or 
more 
1.  Amoxycillin 10 mcg 14 mm 15-16 mm 17 mm 
2.  Erythromycin 15 ≤ 13 14-22 ≥ 23 
3.  Doxycycline 30 ≤ 12 13-15 ≥ 16 
4.  Cephalexin 30 ≤ 14 15-17 ≥ 18 
5.  Ofloxacin 5 ≤ 12 13-15 ≥ 16 
6.  Ciprofloxacin 5 ≤ 15 16-20 ≥ 21 
7.  Gentamycin 10 ≤ 12 13-14 ≥ 15 
8.  Cefotaxime 30 ≤ 22 23-25 ≥ 26 
9.  Ceftazidime 30 ≤ 17 18-20 ≥ 21 
10. Linezolid 30 - - ≥ 21 
11. Amikacin 30 ≤14 15-16 ≥ 17 
12. Imipenem 10 ≤ 19 20-22 ≥ 23 
13. Piperacillin/tazobactum 100/10 ≤ 17 18-20     ≥ 21 
 
 
 
 
 
 
 
ABBREVIATION 
CAP       -        Community Acquired Pneumonia 
HAP      -         Hospital Acquired Pneumonia 
VAP      -         Ventilator Associated Pneumonia 
ETA       -         Endotracheal Aspirate 
CPIS       -         Clinical Pulmonary Infection Score  
PMN       -         Polymorphonuclear cells 
ATCC    -       American Type Culture Collection 
CLSI        -        Central Laboratory Standards Institute 
GNB        -         Gram Negative Bacilli 
GPC        -         Gram Positive Cocci 
CFU      -         Colony Forming Units. 
ESBL     -         Extended Spectrum Beta Lactamase 
E- Test   -        Epsilometer Test 
MHA    -        Mueller Hinton Agar 
MIC      -      Minimum Inhibition Concentration 
PCR     -      Polymerase Chain Reaction 
PBP     -      Pencillin Binding Protein 
SHV    -      Sulphy Hydryl Variable 
TEM    -      Temoniera 
MRSA     -     Methicillin Resistant Staphylococcus aureus 
ESBL      -      Extended Spectrum Beta Lactamases 
MBL       -       Metallo Beta Lactamases  
Amp C     -       Amp C producing Beta Lactamases 
SPSS        -       Stastical Package for the Social Science 
 
 
 
 
KEY TO MASTER CHART 
OP No       -  Outpatient number 
IP No       -  Inpatient number 
CAP         -  Community Acquired Pneumonia 
HAP        -  Hospital Acquired Pneumonia 
VAP        -  Ventilator Associated Pneumonia 
Samples: 
SP          -  Sputum 
B            -  Blood 
E             -  Endotracheal aspirate 
CNP       - Culture negative for pathogen 
NG        -  No growth 
GNB      -  Gram Negative Bacilli 
GPC       -  Gram Positive Cocci 
BS          -  Barlett scoring 
P G10 U  -  Penicillin G 10 Units 
AMX       -  Amoxycillin 
AMC       -  Amoxycillin + Clavulanic acid 
DO          -  Doxycycline 
E            -  Erythromycin 
CN        -  Cephalexin 
CTX      -  Cefotaxime 
CAZ      -  Ceftazidime 
CTR      -  Ceftriaxone 
AK        -  Amikacin 
GEN      -  Gentamicin 
OF         -  Ofloxacin 
CIP       -  Ciprofloxacin 
 
 
COT      -  Cotrimoxazole 
PTZ      -  Piperacillin + Tazobactum 
IMP      - Imipenem 
MRP    -  Meropenem 
VAN    -  Vancomycin 
CX      - Cefoxitin 
S          -  Sensitive 
R         -  Resistant 
MRSA  -  Methicillin Resistant Staphylococcus aureus 
ESBL   -  Extended Spectrum Beta Lactamases 
MBL  -  Metallo Beta Lactamases producers 
Amp C    -  Amp C producing Beta Lactamases 
Outcome: 
EX      -   Expired 
RD      -   Recovered 
LF      -  Lost follow up 
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1 36 M 78455 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP RLL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                               
2 24 F 78510 OP ‒ ‒ ‒ ‒ ‒ no no CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
3 42 M 8670 IM
CU 
 
COP
D  
yes yes ‒ ‒ no no HAP R 
ML 
SP BS  +1,pus 
cells,GPC &GNB 
K.pneumoniae  R   S       R R R S R   R R S S S   R     AM
P C 
  RD 
BS  +1,pus 
cells,GPC pairs 
 E.faecalis R   S S S         S S(HL
G120) 
  S R       S             
B   NG                                                 
4 62 M 78555 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP R 
UL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
5 29 M 79865 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   A,baumanii                                                 
6 63 F 79964 OP ‒ ‒ ‒ ‒ ‒ no no CAP B/L SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
7 68 M 80005 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R S S S S R S S S S S S   S         RD 
B   NG               a                                 
8 19 F 80022 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
9 55 F 8969 OR
TH
O 
DM/
#R 
hand 
yes yes ‒ ‒ no no HAP B/L SP BS  +1,pus 
cells,GNB &GPC 
K.pneumoniae  R   S       R R R R R   R R S S S   S   ESB
L 
    EX 
  s.aureus R   R S S         R S   S S       N
T 
S         RD 
B   NG                                                 
10 22 M 80099 OP  
/CO
PD 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
 K.pneumoniae R   R     R R R R S R S R R S S S   S   ESB
L 
    LF 
B   NG                                                 
11 67 M 80192 OP DM ‒ ‒ ‒ ‒ yes yes CAP L LL SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     R S S S R R S R S S S S   R     AM
P C 
  EX 
B   NG                                                 
12 35 F 80233 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
13 33 M 9065 M
W 
COP
D  
yes yes ‒ ‒ yes yes HAP B/L SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R       S S S S S   S S S S S   S         RD 
14 60 F 9265 IM
CU 
DM 
/ 
COP
D 
YES YES yes ‒ no no VAP R 
ML 
E pus cells,GNB K.pneumoniae R   S       R R R R R   R R S S S   S   ESB
L 
    EX 
B   K.pneumoniae R   S     S R R R R R   R R S S S   S           
15 68 M 80333 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
P.aeruginosa N
T 
  S     N
T 
N
T 
S S S R   R N
T 
S S S   N
T 
        RD 
B   P.aeruginosa N
T 
  S     N
T 
N
T 
S S S R   R N
T 
S S S   N
T 
          
16 25 F 80543 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
17 55 F 80976 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
18 66 M 81234 OP DM ‒ ‒ ‒ ‒ no no CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
 
 
 
19 23 F 81287 OP ‒ ‒ ‒ ‒ ‒ no yes CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
20 65 M 81299 OP DM 
/HT 
‒ ‒ ‒ ‒ yes no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
P.aeruginosa N
T 
  R     N
T 
N
T 
S S R R       S S S   N
T 
        RD 
  B   NG                                                 
21 71 M 82321 OP DM ‒ ‒ ‒ ‒ yes yes CAP L LL SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R R R R R R R R R S S S   S   ESB
L 
    EX 
B   NG                                                 
22 29 M 82354 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
23 42 F 82399 OP DM/
HT 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GNB,GPC 
K.pneumoniae R   S     R R R R S R S R R S S S   S   ESB
L 
      
S.aureus R     R S R R     S R S R R       N
T 
S           
B   S.aureus R     R S R R     S R S R R       N
T 
S           
24 63 M 82432 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     R R R R R R R R R S S S   S   ESB
L 
    RD 
CONS R     S S R S     S R S S R       N
T 
S           
25 30 M 82445 OP ‒ ‒ ‒ ‒ ‒ no no CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
26 55 F 82465 OP ‒ ‒ ‒ ‒ ‒ no no CAP B/L SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
27 38 M 82876 OP COP
D 
‒ ‒ ‒ ‒ no yes CAP B/L SP Few pus cells &no 
organism 
S.marcesens R   S     R S S S S R S S R S S S   N
T 
        RD 
28 64 M 82912 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
P.aeroginosa N
T 
  S     N
T 
N
T 
S S S S       S S S   N
T 
        RD 
29 21 F 82934 OP ‒ ‒ ‒ ‒ ‒ no no CAP L  
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
30 26 F 82965 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
31 49 M 82999 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
32 19 M 83234 OP ‒ ‒ ‒ ‒ ‒ yes no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
33 58 M 83256 OP DM 
/HT 
/CO
PD 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     R R R R S R S R R S S S   S   ESB
L 
    RD 
34 41 M 83324 OP DM ‒ ‒ ‒ ‒ yes yes CAP L  
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     R R R R R R R R R S S S   S   ESB
L 
    LF 
35 65 M 9254 S
W 
DM 
/HT 
/anal 
fissur
e 
yes yes ‒ ‒ yes yes HAP R 
LL 
SP BS  +1,pus 
cells,GNB 
P.aeroginosa R   R       S S S S R   R  S S S   S         RD 
36 59 M 83387 OP DM ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     R R R R R R R R R S S S   S   ESB
L 
    RD 
B   NG                                                 
37 27 F 83432 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
38 68 M 83486 OP DM 
/COP
D 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
S.aureus R     R S R     S S S S S S       N
T 
S         EX 
39 68 M 11643 IM
CU 
DM/H
T/CK
D 
YES YES yes ‒ yes yes VAP L LL E pus cells,GPC 
clusters 
S.aureus R     R S         R R   R R       N
T 
S       
 
 
  RD 
B   NG                                              
40 28 M 83513 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                              LF 
B   NG                                                 
41 61 F 83542 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CONS R     S S R S S     R S S R       N
T 
S         RD 
42 32 M 83562 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
43 29 F 83578 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Bs +1,pus 
cells,GPC IN 
PAIRS 
S.pneumoniae R S   S S R S     S R S R S       N
T 
          RD 
44 63 M 9698 IM
CU 
DM 
/AKI 
yes yes ‒ ‒ yes yes HAP B/L SP Bs +1,pus 
cells,GNCB 
K.pneumonia  R   R       S S S S S   S R S S S   S         RD 
45 58 M 11824 IM
CU 
DM/
HT/
CK
D 
YES YES ‒ y
e
s 
yes yes VAP B/L E pus cells,GNCB A,baumanii R   R       S S S S R   R S S S S   S         RD 
B   NG                                                 
46 61 M 83589 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
47 36 M 83599 OP COP
D 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Bs +1,pus 
cells,GNB 
P.aeroginosa N
T 
  R     N
T 
N
T 
S S S S       S S S   N
T 
        RD 
48 37 F 83632 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
49 21 M 83665 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
50 61 F 83675 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Bs +1,pus 
cells,GNB 
P.aeroginosa N
T 
  R     N
T 
N
T 
R R R S R S  S R R   N
T 
  MB
L 
    RD 
51 59 M 83689 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Bs +1,pus 
cells,GNB 
K.pneumoniae R   S     R R R R R R S R R S S S   S   ESB
L 
    RD 
E.coli R   S     R S S S S S R S R S S S   S           
52 36 M 83698 OP   ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Bs +1,pus 
cells,GPC 
CLUSTERS 
S.aureus R     S S R     S S S S S S       N
T 
S         RD 
53 26 M 83702 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
54 68 M 10321 M
W 
ALD yes yes ‒ ‒ yes yes HAP L LL SP Bs +1,pus 
cells,GNB 
S.marcesecens R   R       S S S S R   R S S S               RD 
55 65 F 83225 OP DM ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R R R R S R R R R S S S   S   ESB
L 
    EX 
E.coli R   R     R S S S S S R S R S S S   S           
56 23 M 83298 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
57 57 M 83345 OP DM ‒ ‒ ‒ ‒ yes yes CAP B/L SP Bs +1,pus 
cells,GNB 
P.aeroginosa N
T 
  R     N
T 
N
T 
S S R R       S S S   N
T 
        RD 
58 28 M 83356 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
59 59 M 83457 OP DM ‒ ‒ ‒ ‒ no yes CAP R 
LL 
SP Bs +1,pus 
cells,GPC 
CLUSTERS 
S.aureus S     S S R     S S S S S S       N
T 
S         RD 
B   S.aureus S     S S R     S S S S S S       N
T 
S           
60 50 F 83567 OP DM/
HT 
‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
61 50 M 83598 OP DM 
/HT 
‒ ‒ ‒ ‒ no yes CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                             
 
 
 
 
 
 
 
 
 
 
    
62 45 M 83678 OP DM ‒ ‒ ‒ ‒ no yes CAP R 
LL 
SP Bs +1,pus 
cells,GNB 
K.pneumoniae R   R     R R R R R R S R R S S S   S   ESB
L 
    RD 
E.coli R   S     R S S S S R S R R S S S   S           
 
63 43 M 83690 OP DM ‒ ‒ ‒ ‒ yes no CAP R 
LL 
SP Bs +1,pus 
cells,GNCB 
K.pneumoniae S   R     S S S S S S S R R S S S   S         RD 
B   K.pneumoniae S   R     S S S S S S 
 
S R R S S S   S           
64 65 F 83721 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Bs +1,pus 
cells,GNCB,GPC  
K.pneumoniae R   R     R S S S S R S R R S S S   S         RD 
S.aureus R     S S R S     S R S R R       N
T 
S           
B   K.pneumoniae R   R     R S S S S R S R R S S S   S           
 
65 62 M 83765 OP DM ‒ ‒ ‒ ‒ yes no CAP R 
LL 
SP Few pus cells &no 
organism 
K.pneumoniae R   S     S S S S S R S R R S S S   S         EX 
B   K.pneumoniae R   R     R S S S S R S R R S S S   S           
66 68 M 83796 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae S   S     S S S S S S S S S S S S   S         RD 
67 28 F 10428 O
G 
AN
C 
yes yes ‒ ‒ no no HAP L 
DIF
FUS
E 
SP BS  +1,pus 
cells,GPC  
 S.aureus R     R R R R     S R R R R       N
T 
R M
R
S
A 
      RD 
B    S.aureus R     S S R S     S R S S S       N
T 
S         
68 54 M 83845 OP DM 
/HT 
‒ ‒ ‒ ‒ no no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
69 64 M 84321 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     S S S S S R S S R S S S   S         EX 
70 54 M 84398 OP DM 
/HT 
‒ ‒ ‒ ‒ no no CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
71 59 F 84435 OP DM ‒ ‒ ‒ ‒ no no CAP R 
UL 
SP BS  +1,pus 
cells,GNB,GPC 
P.aeroginosa N
T 
  R     N
T 
N
T 
S S S R S R  S S S   N
T 
        RD 
CONS R     S S R S     S R S R R       N
T 
S           
72 58 M 84465 OP DM 
/HT 
‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
P.aeroginosa N
T 
  S     N
T 
N
T 
S S S S       S S S   N
T 
        RD 
B   NG                                                 
73 45 F 10531 O
G 
DM 
/HT/
HYS
TER
CTO
MY 
yes yes ‒ ‒ no no HAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
74 57 M 84497 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes yes CAP B/L SP BS  +1,pus 
cells,GPC 
S.aureus S     S S R     S S S S S S       N
T 
S         RD 
75 62 M 84563 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
76 56 F 84598 OP DM ‒ ‒ ‒ ‒ no no CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
78 55 M 84643 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP R 
UL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
79 56 M 13902 IM
CU 
DM/
HT/
DCL
D 
YES YES ‒ y
e
s 
yes no VAP L 
DIF
FUS
E 
E pus cells,GPC 
clusters 
S.aureus R     R R         R R R R R       N
T 
R M
R
S
A 
      EX 
B   S.aureus R     S S R S     S S S R R       N
T 
S           
80 67 M 84734 OP DM ‒ ‒ ‒ ‒ yes yes CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
81 29 F 84756 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
E.coli S   R   R S S S S S R S R R S S S   S         RD 
82 65 M 84799 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP L LL SP BS  +1,pus 
cells,GPC 
CONS R     S S R S     S S S R R       N
T 
          RD 
    B   CONS R     S S R S     S S S R R       N
T 
S           
83 54 M 84888 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP B/L SP Few pus cells &no 
organism 
CNP                                            LF 
B   NG                                                
84 67 M 84897 OP DM ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
P.aeroginosa N
T 
  S     N
T 
N
T 
S S S S       S S S   N
T 
        RD 
85 63 F 84932 OP DM ‒ ‒ ‒ ‒ no no CAP B/L SP Few pus cells &no 
organism 
CNP                                              LF 
B   NG                                                 
86 42 M 10564 OR
TH
O 
 DM 
/ 
#ME
TAR
SAL 
yes yes ‒ ‒ no no HAP R 
DIF
FUS
E 
SP BS  +1,pus 
cells,GNB 
E.coli  R   S       S S S S S   S R S S S   S         RD 
87 41 F 84965 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GPC 
S.aureus R     S S R     S S S S S R       N
T 
S         RD 
B    NG                                                 
88 68 M 84987 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes yes CAP L LL SP BS  +1,pus 
cells,GPC 
S.aureus R     S S R     S S S S S R       N
T 
S         RD 
89 26 M 85112 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
90 52 F 85231 OP DM/
HT 
‒ ‒ ‒ ‒ no no CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
91 69 M 85345 OP DM ‒ ‒ ‒ ‒ yes yes CAP L LL SP BS  +1,pus 
cells,GNB 
S.marcesens R   S     R S S S S S S R S S S S   N
T 
        RD 
92 49 M 85467 OP DM ‒ ‒ ‒ ‒ yes yes CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
93 42 F 10599 M
W 
APD 
/UGI 
Blee
ding 
yes yes ‒ ‒ no no HAP B/L SP BS  +1,pus 
cells,GPC 
 S.aureus R   R S R         S S   S R       N
T 
S         RD 
94 50 M 85543 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
95 23 M 85642 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
96 64 M 85676 OP DM ‒ ‒ ‒ ‒ yes yes CAP L LL SP BS  +1,pus 
cells,GPC 
S.aureus R     S S R     S S S S S R       N
T 
S         LF 
97 48 M 85699 OP DM ‒ ‒ ‒ ‒ yes yes CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
98 47 F 85714 OP DM/
HT 
‒ ‒ ‒ ‒ no no CAP R 
UL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
99 62 M 85765 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP R 
UL 
SP BS  +1,pus 
cells,GNB, 
K.pneumoniae R   S     S S S S S R S S R S S S   S         LF 
B   K.pneumoniae R   S     S S S S S R S S R S S S   S           
100 63 M 85799 OP DM ‒ ‒ ‒ ‒ yes yes CAP R 
UL 
SP BS  +1,pus 
cells,GNB,GPC 
S.aureus R     S S R     S S S S S R       N
T 
S         LF 
K.pneumoniae R   S     R S S S R S R R R S S S   S           
101 66 M 85854 OP DM ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
102 21 M 85876 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
103 65 F 85897 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
104 64 M 85923 OP DM ‒ ‒ ‒ ‒ yes yes CAP R 
UL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae S   S     S S S S R R R S R S S S   S         RD 
P.aeroginosa R   S     N
T 
N
T 
S S S R S R  S S S   N
T 
          
105 65 M 85946 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP R 
UL 
SP BS  +1,pus 
cells,GPC,GNB  
E.coli R   S   S S S S S S S S S S S S S   S         RD 
K.pneumoniae R    
S 
     
S 
S
  
S
  
S
  
S
  
S  S
  
S  S
  
 
S 
 
S 
 
S 
   
S 
          
106 22 M 85966 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
107 64 M 85987 OP DM ‒ ‒ ‒ ‒ no no CAP L LL SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     S S S S S S R S S S S S   S         
 
 
 
 
RD 
108 60 M 11526
4 
IM
CU 
HT/
CV
A 
YES YES yes ‒ yes yes VAP B/L E pus cells,GNB E.coli R   R       S S R R R   R R S S S   R     AM
P C 
  EX 
B   NG                                                 
109 43 M 86012 OP DM ‒ ‒ ‒ ‒ yes no CAP R 
ML 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae S   R     S S S S S R R R R S S S   S         RD 
B                                                     
110 69 M 86045 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     S S S S S S S R R S S S   S         RD 
111 23 F 86057 OP ‒ ‒ ‒ ‒ ‒ no no CAP B/L SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
112 42 M 86089 OP DM ‒ ‒ ‒ ‒ yes no CAP R 
ML 
SP BS  +1,pus 
cells,GNB 
E.coli S   S   R S S S S S S S S R S S S   S         RD 
B   NG                                                 
113 69 M 86123 OP DM ‒ ‒ ‒ ‒ no yes CAP L LL SP BS  +1,pus 
cells,GPC 
S.aureus R     R S R     S S S S S R       N
T 
S         RD 
  B   NG                                                 
114 41 F 86145 OP ‒ 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     S S S S S S S S R S S S   S         RD 
B   NG                                                 
115 40 M 86198 OP COP
D 
‒ ‒ ‒ ‒ no yes CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     S S S S R S S S R S S S   S         RD 
B   NG                                                 
116 69 M 86234 OP DM ‒ ‒ ‒ ‒ no yes CAP R 
UL 
SP BS  +1,pus 
cells,GPC 
CONS R     S S R S     S R S R R       N
T 
S         EX 
117 61 M 10699 OR
TH
O 
DM/ 
BOT
H 
#FOR
EAR
M 
yes yes ‒ ‒ no no HAP B/L SP BS  +1,pus 
cells,GPC 
CONS R   S S S         S R   S R       N
T 
S         RD 
118 39 F 86324 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
119 68 M 86367 OP DM ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS  +1,pus 
cells,GNB 
P.aeroginosa N
T 
  R     N
T 
N
T 
S S S S       S S S   N
T 
        EX 
120 67 M 86432 OP DM ‒ ‒ ‒ ‒ yes no CAP L LL SP BS  +1,pus 
cells,GPC 
S.aureus R     S S R     S S S S S R       N
T 
S         EX 
121 23 M 10789 OR
TH
O 
#han
d 
yes yes ‒ ‒ no no HAP L LL SP BS  +1,pus 
cells,GPC 
 S.aureus R   R R S         S R   R R       N
T 
S         RD 
122 62 F 86487 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
UL 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R S S S R R S S S S S S   S         EX 
CONS R     S S R S     S R S R R       N
T 
S           
123 67 M 86534 OP DM ‒ ‒ ‒ ‒ yes yes CAP R 
ML 
SP BS  +1,pus 
cells,GPC IN 
PAIRS 
S.pneumoniae R S   S S R S     S S S R R       N
T 
          LF 
124 24 M 86576 OP ‒ ‒ ‒ ‒ ‒ yes yes CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
125 61 F 86588 OP DM/
HT 
‒ ‒ ‒ ‒ no no CAP R 
UL 
SP BS  +1,pus 
cells,GPC,GNB  
S.aureus R     S S R S   S S R S S R       N
T 
S         LF 
K.pneumoniae R                                               
126 66 M 86599 OP DM ‒ ‒ ‒ ‒ yes yes CAP RUL SP BS  +1,pus 
cells,GPC,GNB  
K.pneumoniae R   S     R S S S R S S S R S S S   S         LF 
CONS R     S S R S   S S R S S R       N
T 
S           
127 62 M 86604 OP DM 
/HT 
‒ ‒ ‒ ‒ yes yes CAP R 
UL 
SP BS  +1,pus 
cells,GNB 
E.coli R   S   S S S S S S S S S S S S S   S         LF 
128 55 F 86615 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
129 34 M 86624 OP COP
D 
‒ ‒ ‒ ‒ yes yes CAP B/L SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     R S S S R R S S R S S S   S         RD 
130 63 M 86645 OP DM ‒ ‒ ‒ ‒ yes no CAP L LL SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R     R S S S S R S R R S S S   S         LF 
131 33 F 86678 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
UL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                             
 
 
    
 
 
 
132 25 M 10876 IM
CU 
 
COP
D 
yes yes ‒ ‒ no no HAP R 
DIF
FUS
E 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
133 44 F 86745 OP DM ‒ ‒ ‒ ‒ no no CAP R 
UL 
SP BS  +1,pus 
cells,GPC 
S.aureus R     S S R     S S R S R R       N
T 
S         RD 
134 32 F 86834 OP ‒ ‒ ‒ ‒ ‒ no no CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
135 41 M 86897 OP ‒ ‒ ‒ ‒ ‒ yes no CAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
136 52 F 86956 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
UL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
137 67 M 86976 OP DM ‒ ‒ ‒ ‒ yes no CAP LUL SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R S S S S S S R R S S S   S         LF 
138 33 M 86999 OP HT 
/CO
PD 
‒ ‒ ‒ ‒ yes no CAP R 
ML 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R S S S S S S S R S S S   S         RD 
139 25 M 87000 OP ‒ ‒ ‒ ‒ ‒ yes no CAP B/L SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
140 39 F 10976 S
W 
appe
ndici
tis 
/cop
d 
yes yes ‒ ‒ no no HAP LUL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
141 45 M 87015 OP DM 
/HT 
‒ ‒ ‒ ‒ yes no CAP R 
LL 
SP BS  +1,pus 
cells,GNB 
P.aeroginosa N
T 
  R     N
T 
N
T 
S S R R       S S S   N
T 
        RD 
142 34 M 87045 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
UL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
143 26 M 87068 OP ‒ ‒ ‒ ‒ ‒ no no CAP L LL SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
144 65 F 87098 OP DM ‒ ‒ ‒ ‒ no no CAP L LL SP BS  +1,pus 
cells,GNB 
E.coli R   S   R S S S S S S S S R S S S   S         LF 
145 35 M 87134 OP ‒ ‒ ‒ ‒ ‒ no yes CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
146 66 M 87145 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
UL 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
147 45 M 16653 IM
CU 
HE/
CLD 
YES YES yes ‒ yes yes VAP R 
DIF
FUS
E 
E pus cells,GPC 
clusters 
S.aureus R   R R R         S R   R R       N
T 
R M
R
S
A 
      EX 
B   NG                                                 
148 48 M 16202 IM
CU 
HT/
COP
D 
YES YES ‒ y
e
s 
yes no VAP R 
LL 
E Pus cells,GNB p,aeruginosa R   R       S S S S S   S  S S S   S         RD 
B   NG                                                 
 
 
 
 
149 65 M 87245 OP DM 
/HT 
‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS  +1,pus 
cells,GPC,GNB  
K.pneumoniae R   S     R S S S S S S S R S S S   S         RD 
S.aureus R   R R R R       S R   R R       N
T 
R M
R
S
A 
        
150 28 F 18210 IM
CU 
R K 
POI
SON
ING 
YES - ‒ y
e
s 
no no VAP R 
LL 
E pus cells,GNCB A,baumanii R   S       S S S S R   R  S S S   S         RD 
B   NG                                                 
151 71 M 87321 OP DM ‒ ‒ ‒ ‒ no no CAP B/L SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R S S S S S R S S S S S   S         EX 
152 57 M 87356 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP L LL SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   S     R S S S S S R S R S S S   S         RD 
153 38 M 17321 IM
CU 
OPC
POI
SON
ING 
YES YES ‒ y
e
s 
yes yes VAP R 
ML 
E pus cells,GNCB K.pneumoniae R   S       R R R R R   R R S S S   S   ESB
L 
    EX 
B   K.pneumoniae R   S       S S S S S S S S S S S   S           
154 37 M 87435 OP ‒ ‒ ‒ ‒ ‒ no yes CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
155 38 M 87897 OP ‒ ‒ ‒ ‒ ‒ yes no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
156 71 M 17861 IM
CU 
HT/
DM/
ME 
YES - yes ‒ yes yes VAP B/L E pus cells,GNCB A.baumanii R   R       S S S S R   R  S S S   S         RD 
B   NG                                                 
157 31 M 11123 M
W 
ascit
es/H
T/D
M 
yes yes ‒ ‒ yes yes HAP R 
ML 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R       R R R S R   R R S S S   S   ESB
L 
    EX 
158 69 M 88012 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ yes no CAP B/L SP BS  +1,pus 
cells,GPC 
S.aureus R   R R R R     R R R R R R       N
T 
R M
R
S
A 
      RD 
159 43 F 11145 OR
TH
O 
# r 
clavi
cle 
/DM 
yes yes ‒ ‒ no no HAP B/L SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
160 62 M 11265 T
M
W 
DM 
/bro
nchit
is 
yes yes ‒ ‒ yes no HAP L 
ML 
SP BS  +1,pus 
cells,GNB 
K.pneumoniae R   R       S S S S S   S S S S S   S         RD 
161 31 F 88123 OP ‒ ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
162 50 F 17962 IM
CU 
HT/
PE 
YES YES ‒ y
e
s 
no no VAP R 
LL 
E Pus cells,GNB p,aeruginosa R   R       S S S S R   R  S S S            RD 
B   NG                                                 
163 65 M 11287 M
W 
  
LRT
I 
yes yes ‒ ‒ yes no HAP B/L SP BS +1,pus 
cells,GNB,GPC  
E.coli  R   S       S S S S R   R R S S S   S         RD 
 E.fecalis R   S R S         S S(HL
G120) 
  R R       S             
164 27 F 12134 T
M
W 
BA yes yes ‒ ‒ no no HAP B/L SP BS +1,pus 
cells,GNB  
K.pneumonia  R   R       R R R R R   R R S S S   R     AM
P C 
  RD 
A.baumanii R   R       S S S S R   R  S S S   S           
165 63 M 17344 IM
CU 
DM/
HT/
CK
D 
YES YES yes ‒ yes no VAP B/L E pus cells,GNB K.pneumoniae R   S       S S S S S   S R S S S   S         EX 
B   NG                                                 
166 56 M 12354 OR
TH
O 
DM/
HT/
R 
AN
KLE 
DIS 
yes yes ‒ ‒ yes yes HAP B/L SP BS+1,Pus 
cells,GNB, 
K.pneumonia  R   R       R R R S R   R R S S S   S   ESBL     EX 
167 40 M 88567 OP COP
D 
‒ ‒ ‒ ‒ no yes CAP R 
ML 
SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   R     R S S S S R R S R S S S   S         RD 
168 42 F 12654 T
M
W 
 
COP
D / 
yes yes ‒ ‒ no no HAP R 
LL 
SP BS+1,Pus 
cells,GNB, 
P.aeroginosa R   S       S S S S R   R  S S S            RD 
169 62 M 88765 OP DM 
/HT 
‒ ‒ ‒ ‒ no no CAP B/L SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   R     R S S S S R R R R S S S   S         RD 
170 61 M 88890 OP DM ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS+1,Pus 
cells,GNB, 
E.coli R   S   S S S S S S S S S S S S S   S         RD 
171 36 F 19362 IM
CU 
OPC 
POI
SON
ING 
YES - yes ‒ no no VAP B/L E pus cells,GPC 
clusters 
S.aureus R   R S S         R R   R R       N
T 
S         RD 
B   NG                                                 
172 68 M 12765 IM
CU 
DM 
/CV
A 
yes yes ‒ ‒ yes yes HAP B/L SP BS+1,Pus 
cells,GNB, 
P.aeroginosa R   S       S S S R S S S  S S S   S         RD 
173 58 M 12876 OR
TH
O 
DM 
/ 
THR 
yes yes ‒ ‒ yes yes HAP R 
DIF
FUS
E 
SP BS+1,Pus 
cells,GNB, 
E.coli  R   R       R S S S S S R S S S S   S         RD 
174 41 F 89000 OP ‒ ‒ ‒ ‒ ‒ no no CAP B/L SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                                 
175 63 M 12965 M
W 
DM 
/HT 
/AL
D 
yes yes ‒ ‒ yes no HAP B/L SP BS +1,Pus cells 
,GNB ,GPC 
CONS R   S R S         S R   R S       N
T 
S         RD 
K.pneumonia  R   R       S S S R R   R R S S S   S         RD 
176 36 M 12999 OR
TH
O 
R 
Shou
lder 
dislo
catio
n/D
M 
yes yes ‒ ‒ yes yes HAP B/L SP BS+1,Pus 
cells,GNB, 
K.pneumonia R   R       S S S S S   S R S S S   S         RD 
177 60 M 12386 IM
CU 
DM/
CA
D/C
VA 
YES YES yes ‒ yes yes VAP R 
LL 
E pus cells,GNB P.aeroginosa R   R       R S R R R   R  S R R   S       M
B
L 
EX 
B   NG                                                 
178 42 M 89123 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS+1,Pus 
cells,GNB, 
A.baumanii R   S     R S S S S R S R  S S S   N
T 
        RD 
179 60 M 12585 IM
CU 
HT/
PE 
YES YES yes ‒ yes yes VAP B/L E pus cells,GNB E.coli R   S       S S S S S   S R S S S   S         EX 
B   NG                                                 
180 47 M 89342 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS+1,Pus 
cells,GPC 
S.aureus R     R R R     R R R R R R       N
T 
R M
R
S
A 
      RD 
181 55 F 12368
1 
IM
CU 
HT/
COP
D 
YES - yes ‒ no no VAP R 
ML 
E pus cells,GNB K.pneumoniae R   R       R R R S R R R R S S S   R     AM
P C 
  RD 
B   K.pneumoniae R   S     R S S S S S S S S S S S   S           
182 47 F 12676
1 
IM
CU 
HT/
CV
A 
YES YES ‒ y
e
s 
no no VAP B/L E pus cells,GNCB A,baumanii R   S       S S S R R    R S S S   S         RD 
B   NG                                                 
183 61 M 13121 IM
CU 
 / 
TIA 
yes yes ‒ ‒ yes yes HAP B/L SP BS+1,Pus 
cells,GNB, 
E.coli  R   S       S S S S R   R S S S S   S         RD 
184 52 M 13165 T
M
W 
DM 
/ 
BRO
NC
HITI
S 
yes yes ‒ ‒ no no HAP L 
ML 
SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   R       S S S S S   R R S S S   S         RD 
B   K.pneumoniae  R   S        
S 
 
S 
S
  
S
  
S    R  S
  
S
  
S
  
S
  
  S
  
          
185 52 M 12586
1 
IM
CU 
DM/
HT/
CK
D 
YES YES ‒ y
e
s 
yes no VAP B/L E Pus cells,GNB E.coli R   S       S S S R R   R R S S S   S         RD 
B   NG                                                 
186 65 F 89534 OP DM/
HT 
‒ ‒ ‒ ‒ no no CAP R 
UL 
SP BS+1,Pus 
cells,GNB,GPC 
CONS R     S S R     R S R S R R       N
T 
S         EX 
K.pneumoniae R   S                                           
187 70 M 89643 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP B/L SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   S     R S S S S R R R R S S S   S         EX 
188 50 M 12896 IM
CU 
HT/
DCL
D/D
M 
YES YES yes ‒ yes yes VAP R 
LL 
E pus cells,GNB P.aeroginosa R   R       R S R R R   R  S R R   S       M
B
L 
EX 
B   NG                                                 
189 43 M 23967 IM
CU 
DM/
HT/
ME 
YES YES yes ‒ yes no VAP R 
DIF
FUS
E 
E pus cells,GNB E.coli R   S       S S S S R   R R S S S   S         EX 
B   NG                                                 
190 48 M 24400 IM
CU 
OPC 
POI
SON
ING 
YES YES yes ‒ yes yes VAP L LL E pus cells,GNCB A.baumanii R   S       S S S R S   S  S S S   S         RD 
B   NG                                                 
191 69 M 13199 OR
TH
O 
DM 
/ # 
femu
r L 
yes yes ‒ ‒ yes yes HAP R 
ML 
SP BS+1,Pus 
cells,GNB, 
Proteus 
mirabilis 
R   S       S S S S R   R R S S S   S         RD 
192 69 M 24764 IM
CU 
DM/
HT/
CK
D/P
E 
YES YES yes ‒ yes yes VAP B/L E pus 
cells,GNB,GPC  
K.pneumoniae R   S       S S S S S   R R S S S   S         EX 
S.aureus R   R S S         S S   S R       N
T 
S           
  B   NG                                                 
193 38 F 13265 O
G 
DU
B 
/DM 
yes yes ‒ ‒ no no HAP B/L SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   R       R R R R R   R R S S S   S   ESB
L 
    RD 
A.baumanii R   R       S S S R R   R  S S S   S           
194 25 F 26644
1 
IM
CU 
R K 
POI
SON
ING 
YES YES ‒ y
e
s 
no no VAP R 
LL 
E Pus cells,GNB p,aeruginosa R   R       S S S S R   R  S S S   S         RD 
B   NG                                                 
195 61 F 89941 OP DM ‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   S     R S S S S S R R R S S S   S         EX 
196 43 F 89954 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP B/L SP Few pus cells &no 
organism 
CNP                                               LF 
B   NG                                           
 
      
197 64 M 89965 OP DM ‒ ‒ ‒ ‒ no yes CAP R 
LL 
SP BS+1,Pus 
cells,GNB 
K.pneumoniae R   S     R S S S R S S S S S S S   S         RD 
A.baumanii R   S     R S S S S S S S  S S S               
B   NG                                                 
198 68 M 89978 OP DM ‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS+1,Pus 
cells,GNB,GPC 
K.pneumoniae R   R     R S S S R S S S R S S S   S         RD 
S.aureus S   S S S         S S   S S       N
T 
S         RD 
199 65 F 89986 OP DM 
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
ML 
SP BS+1,Pus 
cells,GNB, 
P.aeroginosa N
T 
  S     N
T 
N
T 
S S S R       S S S   N
T 
        EX 
200 45 M 27643 IM
CU 
HT/
CV
A 
YES YES yes ‒ yes no VAP R 
ML 
E pus cells,GNB K.pneumoniae R   S       R R R R R   R R S S S   S   ESB
L 
    EX 
B   NG                                                 
201 29 F 13654 S
W 
 
LIP
OM
A 
yes yes ‒ ‒ no no HAP B/L SP BS+1,Pus 
cells,GNB, 
E.coli R   R       R R R R R   R R S S S   R     AM
P C 
  EX 
202 40 F 29693 IM
CU 
HT/
COP
D 
YES YES ‒ y
e
s 
no no VAP B/L E pus cells,GPC 
clusters 
S.aureus R   R R R         R R   S R       N
T 
S         RD 
B   NG                                                 
203 35 F 90022
3 
OP  
/CO
PD 
‒ ‒ ‒ ‒ no no CAP B/L SP BS+1,Pus 
cells,GNB, 
K.pneumoniae, R   S     R S S S R S S S R S S S   S         RD 
E.coli                                                 
204 41 F 90034
2 
OP  
/CO
PD 
‒ ‒ ‒ ‒ no no CAP R 
LL 
SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   R     R S S S R S R S R S S S   S         RD 
205 37 F 90041
2 
OP  
/CO
PD 
‒ ‒ ‒ ‒ no no CAP B/L SP BS+1,Pus 
cells,GNB, 
K.pneumoniae R   S     R S S S R S R S R S S S   S         RD 
B     R   S                                           
 
